[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 59 of about 59
1. Joyce DL, Hong K, Fishman EK, Wisell J, Pawlik TM: Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. World J Surg Oncol; 2008;6:80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension.
  • BACKGROUND: VIPomas are rare neuroendocrine tumors poorly described in the literature.
  • Aggressive resection of patients with advanced VIPoma neuroendocrine tumors has rarely been reported.
  • A three-dimensional (3-D) pancreas protocol computed tomography scan revealed an 18 x 12 cm pancreatic VIPoma abutting the liver, stomach, spleen, left adrenal, colon that also invaded the distal duodenum - proximal jejunum at the ligament of Treitz in association with sinistral portal hypertension.
  • Following preoperative proximal splenic artery embolization, the patient with underwent successful en bloc resection of the locally advanced VIPoma in conjunction with a diaphragmatic resection, total gastrectomy, splenectomy, left adrenalectomy, as well as small and large bowel resection.
  • The patient is alive and disease-free.
  • CONCLUSION: This case illustrates the role of aggressive resection of pancreatic neuroendocrine tumors and highlights several key technical points that allowed for successful resection.
  • [MeSH-major] Hypertension, Portal / complications. Pancreatic Neoplasms / surgery. Vipoma / surgery

  • Genetic Alliance. consumer health - Portal hypertension.
  • Genetic Alliance. consumer health - VIPoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreatology. 2001;1(6):610-24 [12120244.001]
  • [Cites] World J Surg. 2008 Mar;32(3):476-82 [18175174.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):379-93 [3031836.001]
  • [Cites] South Med J. 1990 Sep;83(9):1021-4 [2402643.001]
  • [Cites] Curr Probl Surg. 1994 Feb;31(2):77-156 [7904550.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Surg Today. 1996;26(6):442-5 [8782305.001]
  • [Cites] West J Med. 1996 Nov;165(5):294-300 [8993200.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):320-5 [9529483.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):429-38 [9742926.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):679-90 [10370596.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):607-11 [16627229.001]
  • [Cites] Transpl Int. 2007 Nov;20(11):947-55 [17617180.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):382-93 [17510774.001]
  • [Cites] Indian J Gastroenterol. 2002 Nov-Dec;21(6):227-8 [12546175.001]
  • (PMID = 18662399.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2517072
  •  go-up   go-down


2. Shaib W, Mitchell K, Saif MW: Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. Yale J Biol Med; 2010 Mar;83(1):27-33
Genetic Alliance. consumer health - VIPoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.
  • Vasoactive intestinal polypeptide secreting islet cell tumors (VIPomas) are neuroendocrine tumors that secrete excessive amounts of vasoactive intestinal polypeptide (VIP) that cause distinct syndromes characterized by large-volume diarrhea, hypokalemia, and dehydration.
  • The annual incidence of these tumors is estimated to be about one per 10,000,000 individuals in the general population.
  • We report a successful treatment of VIPoma with hepatic chemoembolization of a metastatic hepatic lesion evidenced by a reduction of VIP levels and resolutions of symptoms in a patient with pancreatic VIPoma unresponsive to increased doses of an octreotide analog.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Embolization, Therapeutic. Hepatic Artery / surgery. Octreotide / therapeutic use. Vasoactive Intestinal Peptide / metabolism. Vipoma
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):511-25 [11459268.001]
  • [Cites] Med Oncol. 2002;19(3):181-7 [12482130.001]
  • [Cites] Pancreas. 2004 Jan;28(1):93-7 [14707737.001]
  • [Cites] Gastroenterology. 1985 Jan;88(1 Pt 1):185-7 [2856877.001]
  • [Cites] Gastroenterology. 1987 Feb;92(2):527-31 [2878857.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):379-93 [3031836.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Dec;119(4):561-6 [2849276.001]
  • [Cites] Dig Dis Sci. 1989 Mar;34(3 Suppl):28S-39S [2537716.001]
  • [Cites] Endocrinol Metab Clin North Am. 1989 Jun;18(2):545-56 [2545444.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Apr;30(4):385-8 [2557179.001]
  • [Cites] Radiology. 1990 Nov;177(2):549-53 [2171015.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1647-50 [1382492.001]
  • [Cites] Acta Oncol. 1993;32(2):203-8 [8391832.001]
  • [Cites] Surgery. 1994 Dec;116(6):1111-6; discussion 1116-7 [7985095.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2273-8 [7629220.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2768-75 [7673422.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1998 Dec;61(12):748-54 [9884450.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 2:S31-8 [10399030.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Aug-Sep;28(8-9):797-800 [15646540.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1590-602 [16134179.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):87-109 [17382267.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2986-91 [17505000.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):237-54 [18221040.001]
  • [Cites] World J Surg. 2008 May;32(5):930-8 [18324347.001]
  • [Cites] Neuroendocrinology. 2008;88(1):53-8 [18285678.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S111-4 [11762335.001]
  • (PMID = 20351979.001).
  • [ISSN] 1551-4056
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 37221-79-7 / Vasoactive Intestinal Peptide; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2844690
  • [Keywords] NOTNLM ; VIPoma / hepatic artery chemoembolization
  •  go-up   go-down


3. Adam N, Lim SS, Ananda V, Chan SP: VIPoma syndrome: challenges in management. Singapore Med J; 2010 Jul;51(7):e129-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VIPoma syndrome: challenges in management.
  • Vasoactive intestinal peptide-producing tumour (VIPoma) or Verner-Morrison syndrome is a very rare neuroendocrine tumour.
  • It occurs in less than ten percent of all pancreatic islet cell tumours, and about 70 percent to 80 percent of these tumours originate from the pancreas.
  • It may be curative in forty percent of patients with benign and non-metastatic disease.
  • Palliative surgery is indicated in extensive disease, followed by conventional somatostatin analogue (octreotide) therapy.
  • Somatostatin analogues improve hormone-mediated symptoms, reduce tumour bulk and prevent local and systemic effects.
  • We present a female patient with VIPoma syndrome, which had metastasised to the liver at diagnosis.
  • Unfortunately, after symptomatic improvement for three years, her disease progressed.
  • [MeSH-major] Liver Neoplasms / secondary. Palliative Care. Pancreatic Neoplasms / pathology. Vipoma / secondary
  • [MeSH-minor] Catheter Ablation / methods. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Octreotide / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - VIPoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730389.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] RWM8CCW8GP / Octreotide
  •  go-up   go-down


Advertisement
4. Moug SJ, Leen E, Horgan PG, Imrie CW: Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology; 2006;6(1-2):155-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma.
  • BACKGROUND: Vasoactive intestinal peptide-secreting tumours (VIPomas) are rare islet cell tumours of the pancreas that can result in life-threatening biochemical abnormalities.
  • The optimal intervention for metastatic VIPoma remains undecided.
  • This case history documents the clinical role of radiofrequency (RF) ablation in the treatment of metastatic VIPoma.
  • CASE HISTORY: A primary pancreatic VIPoma was diagnosed in a 61-year-old female in 1998 and a distal pancreatectomy and splenectomy were performed.
  • She remained disease-free for 44 months when she presented as an emergency with watery diarrhoea, hypokalaemia, renal failure and an elevated serum VIP level.
  • She remained disease-free until 22 months later when watery diarrhoea resumed and a new hepatic metastasis was seen on CT.
  • The patient remains disease- and symptom-free 10 months after the second RF ablation.
  • CONCLUSION: This case illustrates that the pronounced clinical and biochemical upset caused by metastatic VIPoma can be resolved safely, quickly and repeatedly by RF ablation.
  • [MeSH-major] Catheter Ablation. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Pancreatic Neoplasms / pathology. Vipoma / pathology
  • [MeSH-minor] Biomarkers. Female. Humans. Middle Aged. Neoplasm Metastasis. Pancreatectomy. Splenectomy. Tomography, X-Ray Computed. Treatment Refusal

  • Genetic Alliance. consumer health - VIPoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel and IAP
  • (PMID = 16354964.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


5. Rigabert J, De Clermont H: [Diagnostic procedures and more particularly, place of scintigraphy in neuroendocrine tumors, example of vipoma in MEN 1]. Ann Endocrinol (Paris); 2007 Jun;68(2-3):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic procedures and more particularly, place of scintigraphy in neuroendocrine tumors, example of vipoma in MEN 1].
  • [Transliterated title] Outils diagnostiques et plus particulièrement, place de la scintigraphie dans les tumeurs neuroendocrines: l'exemple d'un vipome dans une NEM de type 1.
  • Functioning endocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1) are rare.
  • We present a case of a symptomatic neuroendocrine tumor in a 27-year old woman.
  • The identification of the nature of the neuroendocrine tumors was difficult despite the use of a wide range of diagnostic procedures.
  • This case is interesting in many ways: this is an exceptional illustration of MEN 1 with vipoma associated with calcitonin secretion and it is also a good example of the benefits and limitations of each diagnostic procedure in the heterogeneous group of neuroendocrine tumors.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / diagnosis. Neuroendocrine Tumors / diagnosis. Vipoma / diagnosis

  • Genetic Alliance. consumer health - VIPoma.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292846.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 9007-12-9 / Calcitonin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


6. Urdangarin A, Iñiguez G, Benavides C, Castillo C, Castro A, Castillos I, Corredoira Y, Soto N: [Pancreatic VIPoma. Report of one case]. Rev Med Chil; 2010 Jul;138(7):841-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic VIPoma. Report of one case].
  • [Transliterated title] VIPoma pancreático. Caso clínico.
  • Neuroendocrine tumors are uncommon, including VIPoma that produces vasoactive intestinal polypeptide.
  • An abdominal CAT scan showed a solid tumor in the body of the pancreas.
  • A fine needle aspiration biopsy of the tumor was compatible with a neuroendocrine tumor.
  • The patient was subjected to a partial pancreatectomy, excising a 4 cm diameter tumor.
  • The pathological study was compatible with a neuroendocrine carcinoma.
  • During the postoperative period the results of serum vasoactive intestinal polypeptide were received.
  • [MeSH-major] Pancreatic Neoplasms / pathology. Vipoma / pathology
  • [MeSH-minor] Carcinoma, Neuroendocrine / pathology. Diagnosis, Differential. Diarrhea / diagnosis. Female. Humans. Middle Aged. Vasoactive Intestinal Peptide / blood

  • Genetic Alliance. consumer health - VIPoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043079.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


7. Amrilleva V, Slater EP, Waldmann J, Bonorden D, Fendrich V: A Pancreatic Polypeptide-Producing Pancreatic Tumor Causing WDHA Syndrome. Case Rep Gastroenterol; 2008;2(2):238-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Pancreatic Polypeptide-Producing Pancreatic Tumor Causing WDHA Syndrome.
  • We report the case of a 46-year-old female patient with WDHA (watery diarrhea/hypokalemia/achlorhydria) syndrome caused by a pancreatic polypeptide-producing tumor in the head of the pancreas.
  • Whereas VIP and other pancreatic endocrine hormones were in the normal range, only serum levels of pancreatic polypeptide were elevated.
  • Imaging studies identified a pancreatic tumor in the head of the gland.
  • After laparotomy, the tumor of 3 cm in size was enucleated.
  • Final pathology documented a pancreatic endocrine tumor with immunohistochemical staining demonstrating the presence of pancreatic polypeptide.
  • The present case illustrates that, although rare, WDHA syndrome may be associated with a pancreatic polypeptide-secreting endocrine tumor of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1980;14(1):11-20 [6991821.001]
  • [Cites] Lancet. 1978 Dec 2;2(8101):1200-1 [82163.001]
  • [Cites] Development. 1991 Dec;113(4):1257-65 [1811941.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3 [17122609.001]
  • [Cites] Pancreatology. 2006;6(1-2):77-85 [16327283.001]
  • [Cites] Am J Pathol. 1983 Nov;113(2):134-42 [6314815.001]
  • [Cites] Cent Afr J Med. 1980 Sep;26(9):195-7 [6258796.001]
  • [Cites] World J Surg. 1979 Sep 20;3(5):587-95 [516776.001]
  • [Cites] Endocrinology. 1968 Dec;83(6):1323-30 [4880986.001]
  • [Cites] Am J Pathol. 1976 Dec;85(3):675-84 [998736.001]
  • [Cites] Semin Gastrointest Dis. 1999 Oct;10(4):156-72 [10548409.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(2-3):153-6 [12794252.001]
  • [Cites] Pancreatology. 2004;4(5):417-33; discussion 434-5 [15249710.001]
  • [Cites] Pancreatology. 2006;6(1-2):7-16 [16327280.001]
  • [Cites] Arch Surg. 1984 May;119(5):508-14 [6143548.001]
  • (PMID = 21490894.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3075149
  • [Keywords] NOTNLM ; Endocrine pancreatic tumor / Pancreatic polypeptide / WDHA syndrome
  •  go-up   go-down


8. Ikuta S, Yasui C, Kawanaka M, Aihara T, Yoshie H, Yanagi H, Mitsunobu M, Sugihara A, Yamanaka N: Watery diarrhea, hypokalemia and achlorhydria syndrome due to an adrenal pheochromocytoma. World J Gastroenterol; 2007 Sep 14;13(34):4649-52
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Watery diarrhea, hypokalemia and achlorhydria (WDHA) syndrome caused by vasoactive intestinal polypeptide (VIP) -producing tumor only rarely occurs in patients with nonpancreatic disease.
  • A 49-year-old woman was referred for evaluation of a right adrenal tumor incidentally diagnosed by abdominal ultrasound during the investigation of chronic watery diarrhea.
  • Laboratory findings showed hypokalemia and excessive production of VIP and catecholamines.
  • After surgical resection of the tumor, diarrhea subsided and both electrolytes and affected hormone levels normalized.
  • Immunohistochemical examination confirmed a diagnosis of pheochromocytoma, which contained VIP-positive ganglion-like cells.
  • [MeSH-major] Achlorhydria / etiology. Adrenal Gland Neoplasms / diagnosis. Diarrhea / etiology. Hypokalemia / etiology. Incidental Findings. Pheochromocytoma / diagnosis. Vipoma / diagnosis
  • [MeSH-minor] Adrenalectomy. Catecholamines / blood. Female. Humans. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome. Vasoactive Intestinal Peptide / blood


9. Kibria R, Ahmed S, Ali SA, Barde CJ: Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma. South Med J; 2009 Jul;102(7):761-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma.
  • The watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vasoactive intestinal polypeptide (VIP)-producing tumors, is an extremely rare cause of hypokalemic rhabdomyolysis and the literature is limited to one case report.
  • Further evaluation revealed that he had a VIP-producing pancreatic neuroendocrine tumor (NET), which was the cause of his hypokalemic rhabdomyolysis.
  • [MeSH-major] Hypokalemia / complications. Pancreatic Neoplasms / diagnosis. Rhabdomyolysis / etiology. Vipoma / diagnosis
  • [MeSH-minor] Achlorhydria / etiology. Adult. Diarrhea / etiology. Humans. Male. Syndrome. Vasoactive Intestinal Peptide / blood


10. Nakayama S, Yokote T, Kobayashi K, Hirata Y, Hiraiwa T, Komoto I, Miyakoshi K, Yamakawa Y, Takubo T, Tsuji M, Imamura M, Hanafusa T: VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. Endocrine; 2009 Apr;35(2):143-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.
  • We report a case of VIPoma in a 72-year-old female patient who presented with excessive diarrhea, severe hypokalemia, and acidemia.
  • No primary tumor site was found by conventional techniques, including contrast-enhanced CT and MRI, angiography, endoscopy, and positron emission tomography (PET), but a tumor was subsequently found in the head of the pancreas by octreotide scanning.
  • Her diarrhea diminished dramatically after octreotide treatment, while her diarrhea has ceased without the therapy of octreotide at the first admission in the course of 2 years of her disease.
  • Immunohistochemial analysis of the excised tumor tissue revealed the expression of both vasoactive intestinal peptide (VIP) and VIP and pituitary adenylate cyclase-activating peptide 1 (VPAC1) receptors.
  • This is the first case report of a VIPoma that immunostains for VIP and VPAC1 receptors and indicates that abundant VIP produced by VIPoma might inhibit its growth and reduce VIP secretion via the VPAC1 receptor in vivo.
  • [MeSH-major] Pancreatic Neoplasms / chemistry. Pancreatic Neoplasms / diagnosis. Receptors, Vasoactive Intestinal Peptide / analysis. Receptors, Vasoactive Intestinal Polypeptide, Type I / analysis. Vipoma / chemistry. Vipoma / diagnosis
  • [MeSH-minor] Achlorhydria / etiology. Aged. Diarrhea / etiology. Female. Gene Expression. Humans. Hypokalemia / etiology. Immunohistochemistry. Indium Radioisotopes. Isotope Labeling. Magnetic Resonance Imaging. Octreotide / therapeutic use. Syndrome. Tomography, X-Ray Computed. Vasoactive Intestinal Peptide / blood

  • Genetic Alliance. consumer health - VIPoma.
  • Genetic Alliance. consumer health - WDHA syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184565.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Receptors, Vasoactive Intestinal Peptide; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 37221-79-7 / Vasoactive Intestinal Peptide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


11. Remme CA, de Groot GH, Schrijver G: Diagnosis and treatment of VIPoma in a female patient. Eur J Gastroenterol Hepatol; 2006 Jan;18(1):93-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of VIPoma in a female patient.
  • We report a case of VIPoma in an 83-year-old female patient, who presented with frequent and excessive diarrhoea, muscle weakness, and severe hypokalaemia.
  • Laboratory analysis showed elevated levels of both vasoactive intestinal polypeptide (VIP; 153 pmol/l) and pancreatic polypeptide (161 pmol/l).
  • In view of the patient's age, physical condition, and tumour size, surgical resection was not performed.
  • The VIPoma syndrome is caused by a neuroendocrine tumour, usually located in the pancreas, which secretes VIP, causing severe diarrhoea, dehydration and hypokalaemia.
  • Treatment options include resection of the tumour, chemotherapy or the reduction of symptoms with somatostatin analogues.
  • [MeSH-major] Pancreatic Neoplasms / radiography. Vipoma / radiography

  • Genetic Alliance. consumer health - VIPoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357627.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


12. Onozawa M, Fukuhara T, Minoguchi M, Takahata M, Yamamoto Y, Miyake T, Kanagawa K, Kanda M, Maekawa I: Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1. Jpn J Clin Oncol; 2005 Sep;35(9):559-63
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1.
  • Laboratory findings showed elevated muscular enzymes, severe hypokalemia and excessive production of catecholamines and vasoactive intestinal polypeptide (VIP).
  • After she underwent surgical removal of the tumor, all the symptoms and signs subsided.
  • A histological study revealed that the mass consisted of pheochromocytoma and ganglioneuroma, respectively producing catecholamines and VIP.
  • We concluded that the patient had hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia and achlorhydria (WDHA) syndrome, which was induced by a VIP-producing composite pheochromocytoma.
  • Composite pheochromocytoma is a neuroendocrine tumor that is composed of pheochromocytoma and ganglioneuroma, both derived from the neural crest.
  • [MeSH-major] Achlorhydria / etiology. Adrenal Gland Neoplasms / complications. Diarrhea / etiology. Hypokalemia / etiology. Neurofibromatosis 1 / complications. Pheochromocytoma / complications. Rhabdomyolysis / etiology. Vasoactive Intestinal Peptide / metabolism


13. Halászlaki C, Horváth H, Kiss L, Takács I, Speer G, Nagy Z, Winternitz T, Dabasi G, Zalatnai A, Patócs A, Lakatos P: [Verner-Morrison syndrome: a case study]. Orv Hetil; 2010 Jul 4;151(27):1111-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verner-Morrison syndrome: a case study].
  • [Transliterated title] Verner-Morrison-szindróma egy esete.
  • Verner and Morrison described a syndrome of watery diarrhea, hypokalemia, and achlorhydria (WDHA) in 1958.
  • VIPomas producing high amounts of vasoactive intestinal peptide (VIP) commonly originate from the pancreas.
  • Typical symptoms play a momentous role in the diagnosis of VIPoma.
  • Morbidity from untreated WDHA syndrome is associated with long-standing dehydration and with electrolyte and acid-base metabolism disorders, which may cause chronic renal failure.
  • Assessment of specific marker (VIP) offers high sensitivity in establishing the diagnosis.
  • Treatment options include resection of the tumor, chemotherapy or the reduction of symptoms with somatostatin analogues.
  • VIPoma cases may be associated with multiple endocrine neoplasia type 1.
  • [MeSH-major] Pancreatic Neoplasms. Vipoma
  • [MeSH-minor] Achlorhydria / etiology. Aged. Biomarkers, Tumor / metabolism. Diarrhea / etiology. Endosonography. Female. Humans. Hypokalemia / etiology. Immunohistochemistry. Magnetic Resonance Imaging. Multiple Endocrine Neoplasia Type 1 / complications. Tomography, X-Ray Computed. Vasoactive Intestinal Peptide / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20558361.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


14. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ: Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg; 2008 Feb;12(2):382-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic VIPomas: subject review and one institutional experience.
  • VIPomas are rare pancreatic endocrine tumors associated with a well-defined clinical syndrome characterized by watery diarrhea, hypokalemia, and metabolic acidosis.
  • The objective of this study was to review a single institution's experience with VIPomas, as well as to review the English literature.
  • A retrospective review of the Johns Hopkins pancreatic database revealed four cases of VIPoma, with three patients being male.
  • Computed tomography revealed the primary pancreatic tumor in all patients, with three tumors located in the tail of the pancreas.
  • One tumor involved the entire pancreas.
  • Mean serum vasoactive intestinal polypeptide levels were 683 pg/ml (range 293 to 1,500 pg/ml).
  • All patients underwent resection of the pancreatic primary tumor.
  • One patient died of progressive metastatic disease 96 months after surgery, whereas the other three remain alive.
  • Extended, meaningful survival can be achieved for VIPoma patients, combining an aggressive surgical approach with additional strategies for treatment of unresected disease.
  • [MeSH-major] Pancreatic Neoplasms / surgery. Vipoma / surgery
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Diarrhea / etiology. Humans. Liver Neoplasms / secondary. Pancreatectomy. Tomography, X-Ray Computed. Vasoactive Intestinal Peptide / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510774.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  • [Number-of-references] 64
  •  go-up   go-down


15. Johnston PC, Ardill JE, Johnston BT, Mc Cance DR: Vasoactive intestinal polypeptide secreting pancreatic tumour with hepatic metastases: long term survival after orthotopic liver transplantation. Ir J Med Sci; 2010 Sep;179(3):439-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vasoactive intestinal polypeptide secreting pancreatic tumour with hepatic metastases: long term survival after orthotopic liver transplantation.
  • BACKGROUND: VIPomas are rare neuroendocrine tumours, with metastases often confined to the liver.
  • AIMS: To discuss the role of orthotopic liver transplantation for neuroendocrine tumours including VIPomas.
  • METHODS: We describe the case of a very rare pancreatic VIPoma, the therapeutic modalities employed, including orthotopic liver transplantation, and present the results of a relevant literature search.
  • RESULTS: This case is the longest (25 years) reported in the literature for survival from a VIPoma after initial diagnosis and long term survival after liver transplantation (9 years).
  • CONCLUSION: Liver transplantation for metastatic VIPomas confined to the liver may be justified in selected patients to provide symptomatic hormonal control and pain from tumour bulk, provided there is no extra hepatic disease and medical treatment has been exhausted.
  • [MeSH-major] Pancreatic Neoplasms / secretion. Vasoactive Intestinal Peptide / secretion. Vipoma / secretion

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825477.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


16. Francesconi AB, Matos M, Lee JC, Wyld DK, Clouston AD, Macfarlane D: Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Ann Nucl Med; 2009 Jul;23(5):497-9
Genetic Alliance. consumer health - VIPoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis.
  • "Slight focal" pancreatic abnormalities using (111)In-pentetreotide imaging has been reported in patients with hyperinsulinaemic hypoglycaemia, confirmed histologically as nesidioblastosis.
  • We describe a 60-year-old man who presented with a 1-year history of intermittent faecal urgency and refractory diarrhoea, non-specific laboratory results, negative imaging results (CT, MRI and EUS), a FNA biopsy that was inconclusive, but suggested an endocrine cell neoplasm, and a (111)In-pentetreotide scan that showed a moderately intense focal uptake clearly localised to the pancreatic head on a low-dose fusion CT.
  • [MeSH-major] Nesidioblastosis / diagnosis. Nesidioblastosis / metabolism. Pancreas / metabolism. Somatostatin / analogs & derivatives. Vipoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387771.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide
  •  go-up   go-down


17. Ammori BJ, El-Dhuwaib Y, Ballester P, Augustine T: Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas. Hepatogastroenterology; 2005 Mar-Apr;52(62):620-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas.
  • Although neuroendocrine tumors of the pancreas are traditionally managed by laparotomy, these rare neoplasms may be amenable to laparoscopic surgical resection.
  • Two female patients aged 63 and 69 years presented with clinical and biochemical features of an insulinoma and a vasoactive intestinal peptide secreting tumor (VIPoma), and were found on cross-sectional imaging to have 1.2-cm and 4.5-cm solitary tumors in the tail of the pancreas.
  • Histology revealed a benign insulinoma and a malignant VIPoma with lymph node metastases respectively.
  • Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas may be accomplished safely, with preservation of the spleen and splenic vessels in benign disease, and with benefits to the patients in terms of postoperative recovery.
  • [MeSH-major] Insulinoma / surgery. Laparoscopy. Pancreatectomy. Pancreatic Neoplasms / surgery. Vipoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816491.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


18. Song S, Shi R, Li B, Liu Y: Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas; 2009 Oct;38(7):811-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors.
  • OBJECTIVE: To discuss our experience in diagnosing and treating pancreatic vasoactive intestinal peptide-secreting tumors (VIPomas) by summarizing clinical information of 4 patients.
  • METHOD: Clinical manifestations, laboratory examination, imaging features, surgical findings, and pathological findings of 4 patients with VIPoma admitted in our hospital from 1991 to the present are discussed.
  • The pancreatic body and tail were the main locations of lesions.
  • Two tumors were shown in the pancreatic body and tail in 1 patient.
  • Distal pancreatic resection and second resection of hepatic metastatic lesions were performed in 1 patient.
  • Resection of the pancreatic body and tail was done in 1 patient, and pancreatoduodenectomy was performed in another patient.
  • CONCLUSIONS: Typical symptoms play an important role in the diagnosis of VIPoma.
  • Octreotide therapy has advanced the preoperative electrolyte management, and the combination of octreotide, chemotherapy, and surgery may be helpful in metastatic disease.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Vipoma / diagnosis. Vipoma / therapy
  • [MeSH-minor] Adult. Chromogranin A / metabolism. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Middle Aged. Vasoactive Intestinal Peptide / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657309.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


19. Xia Y, Darling TN: Rapidly growing collagenomas in multiple endocrine neoplasia type I. J Am Acad Dermatol; 2007 May;56(5):877-80
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient with MEN-I who exhibited rapid growth of multiple collagenomas after pancreatic enucleation of a vasoactive intestinal peptide-secreting tumor (VIPoma) and excision of multiple pancreatic masses.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / complications. Pancreatic Neoplasms / secondary. Skin Diseases / etiology. Vipoma / surgery

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188781.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


20. Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Safioleas M, Mallas E, Polyzos A: VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology; 2005 Jul-Aug;52(64):1259-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VIPomas: an update in diagnosis and management in a series of 11 patients.
  • BACKGROUND/AIMS: VIPoma is a rare pancreatic endocrine tumor (PET) which secretes excessive amounts of VIP (Vasoactive Intestinal Peptide) that causes a special clinical syndrome characterized by secretory diarrhea, hypokalemia and achlorhydria.
  • Among a total number of 76 patients (pts) with PETs, we present in this study 11 pts with VIPoma syndrome focusing on our diagnostic and therapeutic approach, in parallel with a brief review of the literature.
  • The diagnosis was based upon compatible clinical features and serum VIP values and was supported by the estimation of other peptides and neuroendocrine markers such as gastrin, pancreatic polypeptide and chromogranin-A (CgA).
  • VIP levels at the time of diagnosis were more than 3 or 10 times the upper normal limit in 7/11 (63.6%) or 4/11 (36.4%) pts, respectively.
  • A surgical resection was possible in 7/11 (63.6%) pts, while pts with metastatic disease already or poorly differentiated tumors also received additional treatment with somatostatin analogues and chemotherapy.
  • Liver metastases and poor differentiation of tumors seemed to be negative prognostic factors.
  • Also, surgical treatment, as extensive as possible, in combination with somatostatin analogues or chemotherapy when necessary, may also result in prolonged survival, also in patients with advanced disease.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Vipoma / diagnosis. Vipoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Octreotide / therapeutic use. Pancreatectomy. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001675.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


21. Nanba Y, Oka A, Ohno K: [Severe diarrhea associated with X-linked lissencephaly with absent corpus callosum and abnormal genitalia: a case report of successful treatment with the somatostatin analogue octreotide]. No To Hattatsu; 2007 Sep;39(5):379-82
MedlinePlus Health Information. consumer health - Diarrhea.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the age of 2 years while being treated with the antiallergic formula, he was affected with severe diarrhea that resembled watery diarrhea-hypokalemia-acidosis syndrome (WDHA).
  • Hypoglycemia without hyperinsulinemia was seen during fasting, and plasma vasoactive intestinal polypeptide was not increased when he had WDHA-like diarrhea.
  • Although pancreas of ARX mutant mice revealed an increased number of beta and delta cells, we did not detect the cause of hypoglycemia and secretory diarrhea by pancreatic endocrinology.
  • His urinary findings mimicked the symptoms of Fanconi syndrome, so it was possible that his hyperaldsteronemia affected not only his intestinal tract, but also his renal tubules.

  • Genetic Alliance. consumer health - Diarrhea.
  • Genetic Alliance. consumer health - Lissencephaly X-linked.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879613.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


22. Warner RR: Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology; 2005 May;128(6):1668-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteroendocrine tumors other than carcinoid: a review of clinically significant advances.
  • Only relatively recently has there been an increased clinical recognition and characterization of the heterogeneous group of rare gastroenteropancreatic neuroendocrine neoplasms.
  • This review summarizes the derivation of these tumors and the advances in their diagnosis and treatment over the past decade and a half.
  • They are varied in their biological behavior and clinical courses and, depending on their cell type, can produce different hormones causing distinct clinical endocrine syndromes (insulinoma [hypoglycemia], gastrinoma [Zollinger-Ellison syndrome (ZES)], vasoactive intestinal peptideoma [VIPoma], watery diarrhea, hypokalemia-achlorhydria [WDHA], glucagonoma [glucagonoma syndrome], and so forth).
  • In addition to surgery for cure or palliation (by excision and a variety of other cytoreductive techniques), they each are treated with anti-hormonal agents or drugs targeted to each tumor's specific product or its effects.
  • Because of their usual slow rate of growth it is recommended that, even when they are advanced and incurable, unlike in patients with common and more malignant cancers, patients with neuroendocrine tumors often can be palliated and appear to survive longer when managed with an active approach using sequential multimodality treatment.
  • [MeSH-major] Carcinoma, Neuroendocrine. Gastrointestinal Neoplasms
  • [MeSH-minor] Carcinoid Tumor. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887158.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 222
  •  go-up   go-down


23. de Herder WW: Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):33-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemistry of neuroendocrine tumours.
  • Several circulating or urinary tumour markers can be used for the diagnosis and follow-up of functioning and clinically non-functioning neuroendocrine tumours of the pancreatic islet cells and intestinal tract.
  • Among the specific tumour markers are serotonin and its metabolites--e.g.
  • 5-hydroxyindoleacetic acid (5-HIAA)--in carcinoid tumours and the carcinoid syndrome, insulin and its precursors or breakdown products in insulinoma, and gastrin in gastrinoma.
  • Plasma vasointestinal polypeptide (VIP) determinations have been used in the diagnosis of VIPoma, plasma glucagon for glucagonoma, and serum somatostatin for somatostatinoma.
  • Among the tumour-non-specific markers are: chromogranins, neuron-specific enolase (NSE), alpha-subunits of the glycoprotein hormones, catecholamines, pancreatic polypeptide (PP), ghrelin and adrenomedullin.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Biomarkers / analysis. Carcinoid Tumor / diagnosis. Gastrinoma / diagnosis. Gastrins / analysis. Humans. Insulin / analysis. Insulin / metabolism. Insulinoma / diagnosis. Malignant Carcinoid Syndrome / diagnosis. Pancreatic Neoplasms / diagnosis. Serotonin / analysis. Serotonin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382264.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Gastrins; 0 / Insulin; 333DO1RDJY / Serotonin
  • [Number-of-references] 49
  •  go-up   go-down


24. Zhang WQ, Liu JF, Zhao J, Zhao SY, Xue Y: Tumor with watery diarrhoea, hypokalaemia in a 3-year-old girl. Eur J Pediatr; 2009 Jul;168(7):859-62
MedlinePlus Health Information. consumer health - Diarrhea.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor with watery diarrhoea, hypokalaemia in a 3-year-old girl.
  • Watery diarrhoea, hypokalaemia and achlorhydria (WDHA) syndrome was caused by vasoactive intestinal polypeptide (VIP)-producing tumour.
  • A 3-year-old Chinese girl with watery diarrhoea, abdominal distension and hypokalaemia due to a thoracic paraspinal VIP-secreting ganglioneuroma is reported.
  • Computed tomography scan evidenced a left side paravertebral mass of 4 x 6 cm in the lower thoracic region leading to the blood determination of vasoactive intestinal polypeptide which amounted 830 pmol/L(normal < 25 pmol/L).
  • Surgical removal showed a ganglioneuroma of 160 g and was associated with disappearance of the diarrhoea and normalization of VIP level below 20 pmol/L.
  • Review of the 63 reported cases in children with WDHA showed that many of the cases presented with non-treatable watery diarrhoea, hypokalaemia.
  • Achlorhydria is not necessarily part of the WDHA syndrome.
  • Ganglioneuroblastoma and ganglioneuroma are the commonest tumours.
  • Location of the tumour is variable: abdomen, chest or neck.
  • Surgical resection is the treatment of choice of VIP-producing tumours.
  • [MeSH-major] Diarrhea / etiology. Ganglioneuroma / complications. Ganglioneuroma / diagnosis. Hypokalemia / etiology. Thoracic Neoplasms / complications. Thoracic Neoplasms / diagnosis. Vasoactive Intestinal Peptide / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1990 Aug 15;50(16):5177-83 [2379178.001]
  • [Cites] Gut. 1985 May;26(5):438-44 [2860052.001]
  • [Cites] Arch Dis Child. 1975 Nov;50(11):896-9 [1211964.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):2005-12 [1381992.001]
  • [Cites] Eur J Pediatr. 2003 Jul;162(7-8):511-3 [12739135.001]
  • [Cites] Br Med J (Clin Res Ed). 1981 May 30;282(6278):1767-71 [6786616.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1086-95 [8625212.001]
  • [Cites] Gastroenterology. 1967 Apr;52(4):695-708 [4290095.001]
  • [Cites] Klin Padiatr. 2004 Sep-Oct;216(5):264-9 [15455292.001]
  • [Cites] N Engl J Med. 1975 Jul 24;293(4):155-60 [166313.001]
  • [Cites] Monatsschr Kinderheilkd. 1977 May;125(5):462-3 [876203.001]
  • [Cites] Lancet. 1973 Jul 7;2(7819):14-6 [4123289.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Sep;26(9):549-52 [15342979.001]
  • [Cites] Eur J Pediatr. 1981 Oct;137(2):217-9 [6118274.001]
  • [Cites] Klin Padiatr. 2000 Jul-Aug;212(4):200-5 [10994551.001]
  • [Cites] J Pediatr. 1963 Aug;63:217-26 [14043063.001]
  • [Cites] Am J Med. 1958 Sep;25(3):374-80 [13571250.001]
  • [Cites] Arch Surg. 1967 Dec;95(6):934-6 [6058798.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):389-400 [10089056.001]
  • [Cites] Mayo Clin Proc. 2002 Jan;77(1):97-100 [11795252.001]
  • [Cites] J Pediatr. 1976 Oct;89(4):593-5 [957001.001]
  • [Cites] Dig Dis Sci. 1985 Dec;30(12):1201-7 [3905308.001]
  • [Cites] Neuropeptides. 1993 Feb;24(2):99-103 [8096334.001]
  • [Cites] Prog Brain Res. 1995;104:325-38 [8552777.001]
  • [Cites] Peptides. 2002 Oct;23(10):1803-8 [12383868.001]
  • [Cites] Clin Gastroenterol. 1980 Sep;9(3):633-43 [6107190.001]
  • (PMID = 19101728.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


25. Akerström G, Hellman P: Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):87-109
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery on neuroendocrine tumours.
  • Neuroendocrine tumours of the gastrointestinal tract and pancreas present a major challenge to physicians in their recognition and treatment requirements, and surgical treatment of these tumours has become increasingly important for symptom palliation and survival.
  • For some carcinoid tumours the extent of surgery may depend on tumour size.
  • Midgut carcinoid is the most common cause of the carcinoid syndrome, requiring surgery for primary and mesenteric tumours to minimize the risk for abdominal complications but also for removal of liver metastases to palliate hormonal symptoms.
  • Among endocrine pancreatic tumours, insulinoma and gastrinoma often cause severe symptoms of hormone excess despite their inconspicuous size, but they can be successfully removed with improved pre- and intraoperative localization.
  • Other tumours--glucagonoma, VIPoma, and non-functioning endocrine pancreatic tumours--are often large or metastasizing, but generally require surgical debulking to alleviate hormonal symptoms and have favourable survival.
  • [MeSH-major] Neuroendocrine Tumors / surgery
  • [MeSH-minor] Algorithms. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Gastrinoma / surgery. Glucagonoma / surgery. Humans. Insulinoma / surgery. Intestinal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Models, Biological. Multiple Endocrine Neoplasia Type 1 / complications. Multiple Endocrine Neoplasia Type 1 / surgery. Nesidioblastosis / surgery. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Vipoma / surgery. Zollinger-Ellison Syndrome / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382267.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


26. Menéndez-Skertchly AL, Ortiz-Hidalgo C, Quijano-Orvańanos F, Cervantes-Monteil F, Chousleb-Kalach A, Padilla-Longoria R, Godoy-Valdés S, Vidal-González P, Herrera MF: [Endocrine tumors of the pancreas: experience in the ABC Medical Center]. Rev Gastroenterol Mex; 2006 Jul-Sep;71(3):296-301
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine tumors of the pancreas: experience in the ABC Medical Center].
  • OBJECTIVES: To analyze presentation, diagnosis and treatment of islet cell tumors at the ABC Medical Center.
  • MATERIALS AND METHODS: Medical records of the 7 patients with endocrine tumors diagnosed between 1995 and 2005 were reviewed and analyzed, with emphasis to clinical, biochemical and radiological characteristics, surgical treatment and outcome.
  • RESULTS: There were 3 insulinomas, 1 gastrinoma, 1 VIPoma, and 2 non-functioning tumors.
  • The tumor was localized before surgery in 2 cases.
  • In all patients intraoperative ultrasound confirmed the tumor and enucleation was performed in all three.
  • The patient with gastrinoma was diagnosed by endoscopy in the presence of metastatic disease, therefore no surgical treatment was performed.
  • The patient with VIPoma, presented the typical secretory diarrhea.
  • A tumor in the pancreatic head was found and it was resected by pancreaticoduodenectomy.
  • Both non functioning tumors were found by imaging studies, one benign tumor was treated by central pancreatectomy and the other was malignant and underwent distal en-block pancreatectomy.
  • Immunohistochemistry was positive for VIP in the benign lesion.
  • Two of the 3 malignant tumors have died and one is alive with recurrent disease.
  • CONCLUSIONS: Distribution of islet cell tumors in our series followed the usual patterns.
  • Imaging studies localized the tumor in 7 of the 8 patients.
  • Surgical resection cured all benign tumors.
  • [MeSH-major] Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140051.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


27. Cugat E, Olsina JJ, Rotellar F, Artigas V, Suárez MA, Moreno-Sanz C, Herrera J, Noguera J, Figueras J, Díaz-Luis H, Güell M, Balsells J: [Initial results of the National Registry of Laparoscopic Liver Surgery]. Cir Esp; 2005 Sep;78(3):152-60
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Forty-six patients had cystic lesions (26 simple cysts, 13 polycystic disease, five hydatid cysts and two cystic adenomas).
  • In 28 patients the lesions were solid (four adenomas, six focal nodular hyperplasias, three hemangiomas, four hepatocarcinomas, five colorectal metastases, two lung metastases, one breast metastasis, one malignant melanoma metastasis, one pancreatic vipoma metastasis, and one lymphoma).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420816.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


28. Ruiz-Tovar J, Priego P, Martínez-Molina E, Morales V, Sanjuanbenito A, Lobo E: Pancreatic neuroendocrine tumours. Clin Transl Oncol; 2008 Aug;10(8):493-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic neuroendocrine tumours.
  • INTRODUCTION: Pancreatic neuroendocrine tumours (PNT) are infrequent epithelial neoplasms associated with a better outcome than pancreatic adenocarcinoma.
  • There were 28 insulinomas, eight glucagonomas, three gastrinomas, one VIPoma and one carcinoid.
  • Eight patients presented with nonfunctional tumours.
  • Enucleation was performed in 20 patients, distal pancreatectomy in 16, middle pancreatic resection in four, cephalic pancreatoduodenectomy in two and total pancreatoduodenectomy in one.
  • In six patients, the tumour was not resected.
  • RESULTS: Postoperative complication rate was 22%: six pancreatic fistulas, three intra-abdominal collections, one remnant pancreatitis and one pancreatic pseudocyst.
  • Five patients presented recurrences: three liver metastases and two pancreatic recurrences.
  • Actuarial mean survival was 163 months and was longer in insulinomas, in those tumours completely resected and in tumours with benign histological features.
  • CONCLUSION: Conservative surgery of the pancreas is preferred, but aggressive surgery is indicated when the primary tumour can be controlled.
  • Despite of minimising pancreatic resection, there is a high complication rate, mainly pancreatic fistulas, though they can often be conservatively managed.
  • [MeSH-major] Neuroendocrine Tumors / mortality. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gastrinoma / pathology. Gastrinoma / surgery. Glucagonoma / pathology. Glucagonoma / surgery. Humans. Insulinoma / pathology. Insulinoma / surgery. Male. Middle Aged. Neoplasm Staging. Pancreatic Fistula / pathology. Pancreatic Fistula / surgery. Pancreaticoduodenectomy. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Vipoma / pathology. Vipoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667380.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Melen-Mucha G, Lawnicka H, Kierszniewska-Stepien D, Komorowski J, Stepien H: The place of somatostatin analogs in the diagnosis and treatment of the neuoroendocrine glands tumors. Recent Pat Anticancer Drug Discov; 2006 Jun;1(2):237-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The place of somatostatin analogs in the diagnosis and treatment of the neuoroendocrine glands tumors.
  • Similarly, these drugs are also very effective in the treatment of TSH-secreting adenomas.
  • The introduction of these drugs into therapy of the functional neuroendocrine tumors of the gastrointestinal tract was a crucial step in the treatment.
  • Octreotide and lanreotide are the drugs of choice in the treatment of patients with: VIPoma, glucagonoma and carcinoid syndrome.
  • Somatostatin receptor scintigraphy with OctreoScan has been recommended as the best imaging technique in these tumors in the localization and staging procedure.
  • SS analogs, coupled to radioisotope or cytotoxic drugs, create another class of SS molecules, very promising in the therapy of the endocrine glands tumors and in other tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221040.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  • [Number-of-references] 190
  •  go-up   go-down


30. Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B, Oberg K, Eriksson B, Nyman R: Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors. Acta Radiol; 2007 Mar;48(2):180-5
Hazardous Substances Data Bank. GELATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors.
  • PURPOSE: To report our experience of liver embolization with trisacryl gelatin microspheres (Embospheretrade mark) in patients with metastatic neuroendocrine tumors.
  • Seven patients had midgut carcinoids, two had lung carcinoids, one suffered from a thymic carcinoid, and five had endocrine pancreatic tumors.
  • Eight patients suffered from endocrine symptoms, seven of whom had carcinoid syndrome and one WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome.
  • RESULTS: Partial radiological response was seen after eight embolizations (in six different patients), stable disease was observed after 13 embolizations (after three of these, necroses occurred), while radiological progression was noted after only two embolizations.
  • CONCLUSION: Selective hepatic artery embolization with Embosphere particles is a safe treatment for patients with metastatic neuroendocrine tumors and may lead to partial radiological response as well as symptomatic improvement of disabling endocrine symptoms.
  • [MeSH-major] Acrylic Resins / therapeutic use. Embolization, Therapeutic / methods. Gelatin / therapeutic use. Liver Neoplasms / therapy. Neuroendocrine Tumors / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354139.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / trisacryl gelatin microspheres; 9000-70-8 / Gelatin
  •  go-up   go-down


31. Virgolini I, Traub-Weidinger T, Decristoforo C: Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab; 2005 Jun;19(2):213-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear medicine in the detection and management of pancreatic islet-cell tumours.
  • Over the last decade somatostatin receptor scintigraphy using various derivatives of long-acting somatostatin analogues has gained its place in the management of pancreatic islet-cell tumours.
  • Scintigraphy is based on the high-affinity binding of such somatostatin analogues to receptors over-expressed by these tumour types.
  • Following the introduction of (111)In-DTPA-D-Phe(1)-octreotide, clinical studies with radiolabelled DOTA-Tyr(3)-octreotide and DOTA-Tyr(3)-octreotate derivatives have shown considerable improvement of imaging results with increased tumour uptake.
  • One of the newer developments, (68)Ga-labelled DOTA-Tyr(3)-octreotide, has shown promising results in patients with pancreatic islet-cell tumours, based on the high-affinity binding to the somatostatin receptor subtype 2 in combination with positron emission tomography (PET) technology.
  • Other peptides--such as ligands for the gastrin/CCK2 receptors or vasoactive intestinal peptide (VIP)--have also been studied for imaging pancreatic cell tumours.
  • Whereas small-sized gastrinoma, somatostatinoma, glucagonoma, carcinoid and VIPoma are frequently detected by somatostatin receptor scintigraphy, insulinoma may escape detection due to reduced receptor expression.
  • Following peptide receptor scintigraphy, a change in patient management is reported in up to 30% of patients.
  • When labelled with (90)Y or (177)Lu, some somatostatin analogues have been applied to patients in advanced stages of the disease.
  • [MeSH-major] Adenoma, Islet Cell / radionuclide imaging. Adenoma, Islet Cell / radiotherapy. Islets of Langerhans / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763696.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 51110-01-1 / Somatostatin
  • [Number-of-references] 56
  •  go-up   go-down


32. Keller J, Mueller-Wolf JC, Ahmadi-Simab K, Fibbe C, Rosien U, Layer P: Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans? Dig Dis Sci; 2005 Feb;50(2):276-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans?
  • Increased VIP plasma levels cause severe secretory diarrhea.
  • Moreover, VIP is a major regulator of human intestinal motility.
  • We hypothesized that VIP-mediated intestinal motility disturbances contribute to symptoms in elevated plasma VIP.
  • All subjects randomly received intravenous infusion of saline and 300 pmol/kg x hr VIP for 5 hr.
  • Results showed that VIP but not saline infusion induced netjejunal sodium secretion, watery diarrhea, and cardiovascular effects (P < 0.04).
  • VIP did not alter intestinal motor activity or the mean duration of the interdigestive motility cycle or of phases I and II but nearly halved the duration of phase III (P = 0.0002).
  • We conclude that increased plasma VIP markedly shortens human phase III activity without influencing other motility parameters.
  • Hence, it is unlikely that VIP-mediated small intestinal motor disturbances cause symptoms in VIPOMA.
  • Yet VIP may contribute to terminate phase III motility.
  • [MeSH-major] Gastrointestinal Motility / physiology. Vasoactive Intestinal Peptide / blood
  • [MeSH-minor] Humans. Pancreatic Neoplasms / physiopathology. Vipoma / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745085.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


33. Jarufe NP, Coldham C, Orug T, Mayer AD, Mirza DF, Buckels JA, Bramhall SR: Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg; 2005;22(3):157-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment.
  • AIMS: Neuroendocrine tumours of pancreatic and duodenal origin (NETP) are rare and we present a significant experience from a single centre.
  • RESULTS: Twenty-four patients had functioning tumours (16 insulinomas, 3 gastrinomas, 2 somatostatinomas, 1 vipoma, 1 glucagonoma and 1 carcinoid tumour).
  • Nine functioning tumours and 13 non-functioning had a malignant phenotype.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16043962.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Adham M, Giunippero A, Hervieu V, Courbière M, Partensky C: Central pancreatectomy: single-center experience of 50 cases. Arch Surg; 2008 Feb;143(2):175-80; discussion 180-1
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications included 18 neuroendocrine tumors (11 nonfunctioning), 10 serous and 10 mucinous cystadenomas, 5 intraductal papillary mucinous neoplasms, 3 main pancreatic duct strictures, 2 solid cystic papillary tumors, 1 hydatid cyst, and 1 acinar cell carcinoma.
  • The proximal pancreatic remnant was suture ligated.
  • The distal pancreatic end was anastomosed to a Roux-en-Y jejunal loop (n = 6) or to the stomach (n = 44).
  • Three patients had associated procedures, 1 each for metastatic liver cytoreduction (VIPoma), hydatid liver disease, and pancreatic resection for multifocal mucinous cystadenoma.
  • The mean length of the resected pancreas was 45 mm (range, 20-80 mm) and the mean tumor size was 23 mm (5-60 mm).
  • Complications included the following: 4 patients (8%) had pancreatic anastomotic leak, 5 patients (10%) had acute pancreatitis, 7 patients (14%) had intra-abdominal collection, and 3 patients (6%) had bleeding.
  • One patient with metastatic VIPoma had a liver transplant 9 years postoperatively and is alive.
  • The actuarial 5-year patient and pancreatic remnant survival rates were 98% and 95%, respectively.
  • In our series, central pancreatectomy led to effective preservation of both cephalic and distal pancreatic remnants without a significant increase in postoperative morbidity compared with conventional pancreatectomy.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283143.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M: Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg; 2005 Dec;242(6):757-64, discussion 764-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the outcome of an aggressive surgical approach for duodenopancreatic neuroendocrine tumors (PETs) associated with multiple endocrine neoplasia type 1 (MEN1).
  • All patients with insulinoma or vipoma and 7 of 11 patients with ZES were biochemically cured, including the ZES patients who underwent PPPD.
  • However, 19 of 26 (73%) patients developed new small PETs (<1 cm) in the pancreatic remnant, but no patient had yet detectable metastases on imaging.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. DNA Mutational Analysis. Female. Gastrinoma / pathology. Gastrinoma / surgery. Humans. Insulinoma / pathology. Insulinoma / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Prospective Studies. Statistics, Nonparametric. Treatment Outcome. Vipoma / pathology. Vipoma / surgery

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia type 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1999 Nov;189(5):470-82 [10549736.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):495-505; discussion 505-6 [11573043.001]
  • [Cites] Langenbecks Arch Surg. 2002 Mar;386(8):558-69 [11914931.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):641-7 [12049533.001]
  • [Cites] World J Surg. 2002 Aug;26(8):891-6 [12016472.001]
  • [Cites] World J Surg. 2002 Oct;26(10):1267-71 [12205558.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):748-54 [12808627.001]
  • [Cites] Medicine (Baltimore). 2004 Jan;83(1):43-83 [14747767.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] Ann Surg. 1968 Oct;168(4):641-54 [4300659.001]
  • [Cites] Surgery. 1979 Sep;86(3):475-84 [38521.001]
  • [Cites] Gastroenterology. 1983 Jun;84(6):1524-32 [6840481.001]
  • [Cites] World J Surg. 1984 Aug;8(4):561-74 [6207668.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):230-9 [3548610.001]
  • [Cites] Acta Chir Scand. 1989 Aug;155(8):383-8 [2574521.001]
  • [Cites] N Engl J Med. 1990 Mar 15;322(11):723-7 [1968616.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] Surgery. 1991 Dec;110(6):998-1004; discussion 1004-5 [1684067.001]
  • [Cites] Surgery. 1992 Dec;112(6):1016-22; discussion 1022-3 [1360709.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Mar;23(1):1-18 [7913018.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):320-8; discussion 328-30 [7916560.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):295-8 [7524375.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):488-93; discussion 493-4 [7725733.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] Surgery. 1995 Dec;118(6):973-9; discussion 979-80 [7491542.001]
  • [Cites] World J Surg. 1996 Sep;20(7):872-6; discussion 877 [8678965.001]
  • [Cites] Hepatogastroenterology. 1996 Nov-Dec;43(12):1465-9 [8975949.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Surgery. 1997 Dec;122(6):989-96; discussion, 996-7 [9426411.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):489-94 [9681847.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):455-67 [9683585.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):881-91 [9735139.001]
  • [Cites] Eur J Endocrinol. 1998 Oct;139(4):416-20 [9820618.001]
  • [Cites] Surgery. 1998 Dec;124(6):1043-8, discussion 1048-9 [9854581.001]
  • [Cites] Surgery. 1998 Dec;124(6):1056-61; discussion 1061-2 [9854583.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 6;1447(1):51-6 [10500243.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1317-22 [15517479.001]
  • [Cites] Surgery. 2004 Dec;136(6):1205-11 [15657577.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1425-30 [11038217.001]
  • [Cites] Surgery. 2000 Dec;128(6):958-66 [11114630.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2001 Jun;15(2):213-23 [11472035.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):909-18 [10816635.001]
  • (PMID = 16327485.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1409888
  •  go-up   go-down


36. Dadan J, Wojskowicz P, Wojskowicz A: Neuroendocrine tumors of the pancreas. Wiad Lek; 2008;61(1-3):43-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the pancreas.
  • The neuroendocrine tumors (NET) of the pancreas are very rare lesions with frequency of about 3 to 10 per 1 000 000 inhabitants.
  • The neuroendocrine tumors composes a heterogeneous group of tumors.
  • The gastro-entero-pancreatic tumors (GEP) constitute 70% of all NET and 2% of all digestive system tumors.
  • There have been several attempts to classify those lesions and since 2000 exists WHO classification which divides NET according to malignancy and histologic structure.
  • The most often NET of the pancreas are insulinoma, gastrinoma, glucagonoma, somatostatinoma, VIPoma.
  • There is a recommendation to assay hormonal activity, measure concentration of specific peptides, biogenic amines and hormones produced by NET cells to establish diagnosis.
  • Those tests are useful in monitoring treatment and in prognostication course of the disease.
  • Imaging methods especially useful in localization GEP-NET are: ultrasound (US), endoscopic ultrasound (EUS), somatostatin receptor scintigraphy (SRS), computer tomography (CT), magnetic resonance (MR) and angiography.
  • Surgical treatment depends on progression of disease as well as on localization of tumor and consists in both radical methods and palliative operations.
  • Although NET of pancreas are very rare. they are still important diagnostic and therapeutic problem and requires interdisciplinary co-operation.
  • The neuroendocrine tumors should be treated in centers with highest rank of references.
  • [MeSH-major] Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Gastrinoma / diagnosis. Gastrinoma / metabolism. Gastrinoma / therapy. Glucagonoma / diagnosis. Glucagonoma / metabolism. Glucagonoma / therapy. Humans. Insulinoma / diagnosis. Insulinoma / metabolism. Insulinoma / therapy. Somatostatinoma / diagnosis. Somatostatinoma / metabolism. Somatostatinoma / therapy. Vipoma / diagnosis. Vipoma / metabolism. Vipoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717042.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


37. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumours--analysis of own material--a nine--year retrospective study.
  • BACKGROUND/AIMS: Neuroendocrine tumours are fairly rare neoplasms that require different treatments and have various prognoses.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • METHODOLOGY: Thirty-five cases of neuroendocrine tumours were studied retrospectively in a 9-year period.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • There were 6 cases of neuroendocrine tumours localized in pancreas.
  • CONCLUSIONS: Neuroendocrine tumours occur very rare.
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


38. Berković MC, Altabas V, Herman D, Hrabar D, Goldoni V, Vizner B, Zjacić-Rotkvić V: A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Coll Antropol; 2007 Jun;31(2):531-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
  • The aim of this research was to assess the clinical and biochemical efficacy of the octreotide in the treatment of patients with various functional gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
  • They were diagnosed with VIPoma, glucagonoma, gastrinoma, medullary thyroid carcinoma (solitary and as a part of MEN-II syndrome), pancreatic carcinoids (solitary and as a part of multiple endocrine neoplasia type-1 syndrome-MEN-1 syndrome) and midgut carcinoids.
  • The patients presented with Verner-Morrison, glucagonoma, Zollinger Ellison and carcinoid syndrome respectively.
  • All had a metastatic disease at the time of diagnosis and a positive octreoscan finding.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neuroendocrine Tumors / drug therapy. Octreotide / therapeutic use. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Biomarkers, Tumor. Female. Humans. Male. Malignant Carcinoid Syndrome / drug therapy. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847934.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; RWM8CCW8GP / Octreotide
  •  go-up   go-down


39. Fendrich V, Habbe N, Celik I, Langer P, Zielke A, Bartsch DK, Rothmund M: [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients]. Dtsch Med Wochenschr; 2007 Feb 2;132(5):195-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients].
  • BACKGROUND AND OBJECTIVE: To evaluate the outcome of patients with pancreatic endocrine tumors (PETs) in a tertiary referral centre.
  • The diagnosis of gastrinoma, insulinoma, vipoma and non-functioning PETs was based on clinical symptoms, biochemical tests and histopathology.
  • Enucleation of the tumor and distal pancreatic resections were the main type of operations.
  • After a median follow up of 67 months (range 1-339), 74 of 144 (51%) patients are still alive without evidence of disease.
  • No patient with a benign tumor and no MEN1-patients died because of PETs.
  • The 5, 10, and actuarial 20-year survival rate for patients with malignant tumors were 75%, 70% and 65%, respectively.
  • The survival rate was significantly related to the type of tumor (benign vs. malignant: p = 0.0002), the patients age at time of initial operation (<50 years vs. >50 years: p = 0.0007), the genetic background of the tumor (sporadic vs.
  • [MeSH-major] Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Gastrinoma / mortality. Gastrinoma / surgery. Humans. Insulinoma / mortality. Insulinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Middle Aged. Retrospective Studies. Survival Rate. Survivors / statistics & numerical data. Vipoma / mortality. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252361.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Nijs E, Callahan MJ, Taylor GA: Disorders of the pediatric pancreas: imaging features. Pediatr Radiol; 2005 Apr;35(4):358-73; quiz 457
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this manuscript is to provide an overview of the normal development of the pancreas as well as pancreatic pathology in children.
  • Familiarity with the range of normal appearance and the diseases that commonly affect this gland is important for the accurate and timely diagnosis of pancreatic disorders in the pediatric population.
  • These include pancreas divisum, annular pancreas, agenesis of the dorsal pancreatic anlagen and ectopic pancreatic tissue.
  • Syndromes that can manifest pancreatic pathology include: Beckwith Wiedemann syndrome, von Hippel-Lindau disease and autosomal dominant polycystic kidney disease.
  • Children and adults with cystic fibrosis and Shwachman-Diamond syndrome frequently present with pancreatic insufficiency.
  • In younger children, unexplained pancreatic injury must always alert the radiologist to potential child abuse.
  • Pancreatic pseudocysts are a complication of trauma, but can also be seen in the setting of acute or chronic pancreatitis from other causes.
  • Primary pancreatic neoplasms are rare in children and are divided into exocrine tumors such as pancreatoblastoma and adenocarcinoma and into endocrine or islet cell tumors.
  • Islet cell tumors are classified as functioning (insulinoma, gastrinoma, VIPoma and glucagonoma) and nonfunctioning tumors.
  • Solid-cystic papillary tumor is probably the most common pancreatic tumor in Asian children.
  • Although quite rare, secondary tumors of the pancreas can be associated with certain primary malignancies.
  • [MeSH-major] Diagnostic Imaging. Pancreatic Diseases / diagnosis
  • [MeSH-minor] Adult. Child. Humans. Infant. Pancreas / abnormalities. Pancreas / anatomy & histology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1986 Mar;158(3):629-31 [3511500.001]
  • [Cites] Pediatr Radiol. 1985;15(5):348-9 [3897999.001]
  • [Cites] Pediatr Radiol. 2001 Feb;31(2):92-7 [11214693.001]
  • [Cites] Pediatr Radiol. 1990;20(5):323-5 [2190152.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17 (3):474-6 [8491914.001]
  • [Cites] Eur Radiol. 1998;8(7):1236-44 [9724445.001]
  • [Cites] Pediatr Surg Int. 2001 Nov;17(8):614-20 [11727051.001]
  • [Cites] Pediatr Surg Int. 1998 Jul;13(5-6):428-30 [9639636.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1996 Dec;23 (5):599-603 [8985852.001]
  • [Cites] J Ultrasound Med. 2000 Nov;19(11):757-63 [11065264.001]
  • [Cites] AJR Am J Roentgenol. 1991 Apr;156(4):799-800 [2003448.001]
  • [Cites] Pediatr Radiol. 1989;19(4):242-5 [2748231.001]
  • [Cites] Pediatr Surg Int. 2002 Mar;18(2-3):190-2 [11956796.001]
  • [Cites] Dig Dis Sci. 1987 Oct;32(10):1075-81 [3308373.001]
  • [Cites] AJR Am J Roentgenol. 1983 Oct;141(4):653-5 [6604410.001]
  • [Cites] Curr Opin Pediatr. 2001 Oct;13(5):447-51 [11801891.001]
  • [Cites] Pediatr Radiol. 2001 Jul;31(7):501-6 [11486805.001]
  • [Cites] Radiology. 1988 Feb;166(2):413-6 [3336716.001]
  • [Cites] J Pediatr Surg. 1995 May;30(5):724-6 [7623239.001]
  • [Cites] J Pediatr Surg. 1993 Dec;28(12):1570-1 [8301494.001]
  • [Cites] Radiology. 1979 Nov;133(2):289-95 [573913.001]
  • [Cites] Abdom Imaging. 2001 Nov-Dec;26(6):648-50 [11907732.001]
  • [Cites] Pediatr Radiol. 1995;25(5):356-9 [7567263.001]
  • [Cites] Gastrointest Radiol. 1987;12 (1):18-22 [3792751.001]
  • [Cites] Radiology. 1996 Mar;198(3):875-9 [8628886.001]
  • [Cites] Radiology. 1987 Aug;164(2):479-81 [3602389.001]
  • [Cites] Radiology. 2000 Feb;214(2):476-82 [10671596.001]
  • [Cites] Semin Pediatr Surg. 2000 Nov;9(4):209-15 [11112838.001]
  • [Cites] Radiographics. 1992 Jul;12(4):673-86 [1636033.001]
  • [Cites] Radiology. 1987 Oct;165(1):15-8 [3306783.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):370-4 [8626892.001]
  • [Cites] Radiology. 1985 Feb;154(2):333-7 [3880903.001]
  • [Cites] Radiographics. 1995 Mar;15(2):301-13 [7761636.001]
  • [Cites] AJR Am J Roentgenol. 1982 Sep;139(3):505-10 [6981314.001]
  • [Cites] Radiology. 1983 May;147(2):491-4 [6836127.001]
  • [Cites] Prenat Diagn. 1997 Mar;17 (3):276-80 [9110373.001]
  • [Cites] Pediatr Surg Int. 2001 Sep;17(7):552-4 [11666059.001]
  • [Cites] Radiographics. 1998 Sep-Oct;18(5):1171-87 [9747614.001]
  • [Cites] AJR Am J Roentgenol. 1994 May;162(5):1091-4 [8165988.001]
  • [Cites] Radiology. 1995 Apr;195(1):196-200 [7892468.001]
  • [Cites] AJR Am J Roentgenol. 1991 Aug;157(2):375-9 [1853825.001]
  • (PMID = 15536562.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


41. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer; 2008 Sep 1;113(5):921-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
  • BACKGROUND: There are limited effective treatment options available and a poor 5-year survival for patients with inoperable neuroendocrine liver metastases (NETLMs).
  • Patients were monitored prospectively, and the response to treatment was measured by using cancer markers and tumor size on computed tomography imaging studies.
  • The site of the primary neuroendocrine tumor was the bronchus in 1 patient, the medullary thyroid in 2 patients, gastrointestinal in 15 patients, the pancreas in 8 patients, and of unknown origin in 8 patients.
  • The tumors were classified as vipoma (1 tumor), somatostatinoma (1 tumor), glucagonoma (2 tumors), large cell (3 tumors), carcinoid (25 tumors), and of unknown origin (2 tumors).
  • [MeSH-major] Brachytherapy / methods. Embolization, Therapeutic / methods. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Neuroendocrine Tumors / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18618495.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Yu R, Nissen NN, Dhall D, Heaney AP: Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas; 2008 May;36(4):428-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature.
  • We report a rare case of nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas.
  • A 60-year-old patient was incidentally found to harbor a pancreatic mass with markedly elevated glucagon levels but without glucagonoma syndrome.
  • She was initially diagnosed with glucagonoma, and the tumor was resected.
  • Pathological examination demonstrated that the tumor was a nonfunctioning islet cell tumor and revealed nesidioblastosis and hyperplasia of alpha cells and microglucagonoma in the apparently normal surgical margin.
  • No pancreatic tumors recurred 36 months after surgery.
  • This is the third case of alpha-cell nesidioblastosis reported in the English literature.
  • Nesidioblastosis and hyperplasia of alpha cells should be considered in the differential diagnosis of hyperglucagonemia.
  • Somatostatin analog may be used to suppress glucagon secretion in alpha-cell hyperplasia.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Glucagonoma / pathology. Islets of Langerhans / pathology. Nesidioblastosis / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Islet cell hyperplasia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437091.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer; 2005 Jan 17;92(1):94-101
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
  • Tumour-associated angiogenesis is partly regulated by the hypoxia-inducible factor (HIF) pathway.
  • Endocrine tumours are highly vascularised and the molecular mechanisms of their angiogenesis are not fully delineated.
  • The aim of this study is to evaluate angiogenesis and expression of HIF-related molecules in a series of patients with pancreatic endocrine tumours (PETs).
  • The expression of vascular endothelial growth factor (VEGF), HIF-1alpha, HIF-2alpha and carbonic anhydrase 9 (CA9) was examined by immunohistochemistry in 45 patients with PETs and compared to microvascular density (MVD), endothelial proliferation, tumour stage and survival.
  • Well-differentiated tumours had high cytoplasmic VEGF and HIF-1alpha expression.
  • Contrary to other types of cancer, PETs are highly vascularised, but poorly angiogenic tumours.
  • The regulation of HIF signalling appears to be specific in pancreatic endocrine tumours.
  • [MeSH-major] Adenoma, Islet Cell / blood supply. Adenoma, Islet Cell / metabolism. Neovascularization, Pathologic. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / metabolism. Vascular Endothelial Growth Factors / metabolism
  • [MeSH-minor] Adult. Basic Helix-Loop-Helix Transcription Factors. Carbonic Anhydrases / metabolism. Disease Progression. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit. Male. Microcirculation. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Apr;34(5):609-18 [9713263.001]
  • [Cites] Neuroendocrinology. 1986;43(2):159-65 [3523276.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1309-16 [9815813.001]
  • [Cites] J Pathol. 1998 Nov;186(3):313-8 [10211122.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1388-93 [10728704.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1441-5 [10780524.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):167-71 [11248550.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Nature. 2001 Aug 30;412(6850):877-84 [11528470.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):177-81 [11550286.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):881-90 [11556841.001]
  • [Cites] Novartis Found Symp. 2001;240:212-25; discussion 225-31 [11727931.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):719-25 [11857345.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1276-82 [11953885.001]
  • [Cites] Semin Cell Dev Biol. 2002 Feb;13(1):29-37 [11969369.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2595-604 [12171890.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):45-53; discussion 54 [12210027.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4961-5 [12414859.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):181-5 [12539172.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):18-27 [12605362.001]
  • [Cites] Histopathology. 2003 May;42(5):482-91 [12713626.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):319-23 [7543771.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1196-200 [7590692.001]
  • [Cites] Mol Endocrinol. 1995 Dec;9(12):1760-70 [8614412.001]
  • [Cites] Genomics. 1996 May 1;33(3):480-7 [8661007.001]
  • [Cites] Histopathology. 1997 Mar;30(3):294-301 [9088964.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1417-23 [9358768.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):286-93 [9495200.001]
  • [Cites] Histopathology. 1998 Feb;32(2):133-8 [9543669.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):329-33 [9578082.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Gastroenterology. 2003 Oct;125(4):1094-104 [14517793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • (PMID = 15558070.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factors; 0 / endothelial PAS domain-containing protein 1; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2361752
  •  go-up   go-down


44. Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC: Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398. Peptides; 2009 Dec;30(12):2357-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
  • We used an in vivo model of human experimental prostate cancer in order to shed a new light on the effects of vasoactive intestinal peptide (VIP) on tumor growth as well as its pro-metastatic potential in this disease.
  • The regulatory role of VIP on cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) expression as well as on matrix metalloproteinase-2 and 9 (MMP-2 and 9) activities was examined.
  • A selective COX-2 inhibitor, NS-398, and curcumin were used to block VIP effects.
  • Xenografts of VIP-treated PC3 prostate cancer cells in nude mice gave tumors that grew significantly faster than those in the untreated group.
  • It is conceivably a result of both the trophic effect of VIP on prostate cancer cells and the proangiogenic action of the neuropeptide in the growing tumor.
  • We show the overexpression at mRNA and/or protein levels of VIP, its main receptor VPAC(1), the major angiogenic factor VEGF, and the pro-inflammatory enzyme COX-2 as well as the increased activity of MMP-2 and 9 in tumors derived from VIP-treated PC3 cells as compared with control group.
  • The overexpression of the above biomarkers was suppressed in tumors derived from VIP-treated PC3 cells that had been previously incubated with curcumin or NS-398.
  • Thus, the potential therapeutic role of curcumin and selective COX-2 inhibitors in combination with available VIP antagonists should be considered in prostate cancer therapy as supported by their inhibitory activities on tumor cell growth.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Curcumin / pharmacology. Nitrobenzenes / pharmacology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Sulfonamides / pharmacology. Vasoactive Intestinal Peptide / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclooxygenase 2. Humans. Immunohistochemistry. Male. Matrix Metalloproteinase 2 / metabolism. Mice. Mice, Nude. Polymerase Chain Reaction. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19772879.001).
  • [ISSN] 1873-5169
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 37221-79-7 / Vasoactive Intestinal Peptide; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; IT942ZTH98 / Curcumin
  •  go-up   go-down


45. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C: Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg; 2010 Feb;34(2):249-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.
  • Compared with nonaffected patients, those with thymic tumors (hazard ratio [HR] = 4.64, 95% CI = 1.73-12.41), glucagonomas-vipomas-somatostatinomas (HR = 4.29, 95% CI = 1.54-11.93), nonfunctioning pancreatic tumors (HR = 3.43, 95% CI = 1.71-6.88), and gastrinoma (HR = 1.89, 95% CI = 1.09-3.25) had a higher risk of death after adjustment for age, gender, and diagnosis period.
  • The increased risk of death among patients with adrenal tumors was not significant, but three patients died from aggressive adrenal tumors.
  • Pituitary tumors, insulinomas, and bronchial tumors did not increase the risk of death.
  • CONCLUSIONS: The prognosis of MEN1 disease has improved since 1980.
  • Thymic tumors and duodenopancreatic tumors, including nonsecreting pancreatic tumors, increased the risk of death.
  • Rare but aggressive adrenal tumors may also cause death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Epidemiol Sante Publique. 2003 Feb;51(1 Pt 1):3-30 [12684578.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):935-52 [1677802.001]
  • [Cites] Ann Chir. 2004 Apr;129(3):149-55 [15142812.001]
  • [Cites] Surgery. 2004 Nov;136(5):981-7 [15523390.001]
  • [Cites] Crit Rev Oncol Hematol. 1984;2(2):117-84 [6152202.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] World J Surg. 2002 Aug;26(8):891-6 [12016472.001]
  • [Cites] Surgery. 1979 Sep;86(3):475-84 [38521.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):457-65 [11836268.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):449-51 [15095313.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7798-803 [19047107.001]
  • [Cites] J Clin Epidemiol. 2004 Mar;57(3):243-51 [15066684.001]
  • [Cites] J Epidemiol Biostat. 2000;5(3):169-75 [11051113.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Ann Chir. 2000 Feb;125(2):118-23 [10998796.001]
  • [Cites] World J Surg. 2006 May;30(5):654-62; discussion 663-4 [16680582.001]
  • [Cites] Radiology. 2003 Jul;228(1):15-21 [12832569.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1437-41 [11038219.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Nov;28(11):1075-81 [15657529.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):455-67 [9683585.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1177-83 [9215690.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1169-75 [9215689.001]
  • [Cites] World J Surg. 2004 Jan;28(1):108-11 [14648050.001]
  • [Cites] Am J Med. 1998 Feb;104(2):115-22 [9528728.001]
  • [Cites] QJM. 1996 Sep;89(9):653-69 [8917740.001]
  • [Cites] Am J Med. 1954 Mar;16(3):363-71 [13138607.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):265-72 [16432361.001]
  • [Cites] Surgery. 1995 Dec;118(6):1077-82 [7491526.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1197-207 [19294466.001]
  • [Cites] Orphanet J Rare Dis. 2006 Oct 02;1:38 [17014705.001]
  • (PMID = 19949948.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


46. Fernández-Cruz L, Blanco L, Cosa R, Rendón H: Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg; 2008 May;32(5):904-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?
  • Since the first reports with laparoscopic resection of islet cell tumors in 1996, the experience worldwide is still limited, with only short-term outcomes available.
  • Some have suggested that a malignant tumor is a contraindication to laparoscopic resection.
  • Aim The aim of this study was to evaluate the feasibility, safety, and long-term outcome of the laparoscopic approach in patients with functioning, nonfunctioning, or overt malignant pancreatic neuroendocrine tumor (PNT).
  • Patients and methods A total of 49 consecutive patients (43 women, 6 men; mean age 58 years, range 22-83 years) underwent laparoscopic pancreatic surgery (LPS) from April 1998 to June 2007.
  • Other than 9 PNTs localized in the head of the pancreas, all tumors were located in the left pancreas.
  • There were 33 patients with functioning tumors: 4 with gastrinomas (mean size 1.2 cm), 1 with a glucagonoma (4 cm), 3 with vipomas (3.2 cm), 2 with carcinoids (5.2 cm), 20 with sporadic insulinomas (1.4 cm), 2 with insulinoma/multiple endocrine neoplasia type 1 (MEN-1) (4.4 cm), and 1 with a malignant insulinoma (13 cm).
  • Sixteen patients had a nonfunctioning tumor (mean size 5 cm).
  • Evaluation criteria included operative and postoperative factors, pathologic data including R0 or R1 resection (the pancreatic transection margin and all transection margins on the specimen were inked).
  • Long-term outcomes were analyzed by tumor recurrence and patient survival.
  • The group of patients with malignant tumors undergoing Lap SxDP had a longer operating time and greater blood loss compared with the other distal pancreatectomy (Lap DP) techniques.
  • These complications were mainly pancreatic fistula: 8.7% after Lap DP and 38% after Lap En.
  • Conclusions This series demonstrates that LPS is feasible and safe in benign-appearing and malignant neuroendocrine pancreatic tumors (NEPTs).
  • LPS can achieve negative tangential margins in a high percentage of patients with malignant tumors.
  • [MeSH-major] Carcinoma, Islet Cell / surgery. Laparoscopy. Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1998 Jul;22(7):651-7; discussion 657-8 [9606277.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):819-30 [16253903.001]
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):134-40 [15609056.001]
  • [Cites] Surgery. 1999 Dec;126(6):1105-10 [10598194.001]
  • [Cites] Ann Surg. 2003 May;237(5):650-7; discussion 657-9 [12724631.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):138-45 [16368504.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] World J Surg. 2007 Mar;31(3):579-85 [17219270.001]
  • [Cites] Medicine (Baltimore). 2000 Nov;79(6):379-411 [11144036.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] HPB (Oxford). 2006;8(1):49-56 [18333239.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jul;15(3):497-510 [16882494.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):170-85 [15719379.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1109-16 [8758239.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):103-8 [17008952.001]
  • [Cites] World J Surg. 2004 Dec;28(12 ):1239-47 [15517485.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):488-93; discussion 493-4 [7725733.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1418-24 [11038216.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] Surgery. 1991 Dec;110(6):998-1004; discussion 1004-5 [1684067.001]
  • [Cites] Surgery. 1996 Nov;120(5):885-90 [8909526.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):264-75 [16498592.001]
  • [Cites] Medicine (Baltimore). 1996 Mar;75(2):53-63 [8606627.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):393-8; discussion 398-9 [1973323.001]
  • [Cites] Surgery. 1998 Dec;124(6):1056-61; discussion 1061-2 [9854583.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):752-60 [16773762.001]
  • [Cites] Langenbecks Arch Surg. 2002 Mar;386(8):558-69 [11914931.001]
  • [Cites] World J Surg. 2006 Oct;30(10 ):1916-9; discussion 1920-1 [16855802.001]
  • [Cites] Br J Surg. 2005 May;92(5):539-46 [15852419.001]
  • [Cites] Surgery. 1998 Dec;124(6):1050-5 [9854582.001]
  • [Cites] J R Coll Surg Edinb. 1994 Jun;39(3):187-8 [7932343.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jul;15(3):479-96 [16882493.001]
  • [Cites] Langenbecks Arch Surg. 2000 Aug;385(5):329-36 [11026704.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):819-44 [9735136.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):264-72 [15937909.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):270-4 [15006883.001]
  • [Cites] J Intern Med. 2003 Jun;253(6):590-8 [12755954.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] Digestion. 1994;55 Suppl 3:98-103 [7535270.001]
  • [Cites] Surgery. 2003 May;133(5):521-7 [12773980.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):640-5 [7902072.001]
  • [Cites] Surg Endosc. 1994 May;8(5):408-10 [7915434.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):381-8 [15749601.001]
  • [Cites] Surgery. 2000 Sep;128(3):386-91 [10965308.001]
  • [Cites] Radiology. 2000 Feb;214(2):483-90 [10671597.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3 [17122609.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:227s-230s [12487288.001]
  • [Cites] Surgery. 1984 Dec;96(6):1027-37 [6095477.001]
  • [Cites] Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70 [16924083.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):95-8 [16368497.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1057-65 [12016486.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):477-88 [9681846.001]
  • [Cites] Surg Endosc. 2000 Dec;14 (12 ):1131-5 [11148782.001]
  • [Cites] Surgery. 2000 Dec;128(6):958-66 [11114630.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):881-91 [9735139.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):42-8 [12832964.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1607-21; discussion 1621-2 [17896167.001]
  • [Cites] World J Surg. 2005 Jun;29(6):789-93 [15880279.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):208-12 [15036197.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Liver Transpl. 2007 Mar;13(3):327-33 [17318853.001]
  • [Cites] World J Surg. 2002 Oct;26(10):1297-300 [12205557.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):493-501 [15120376.001]
  • (PMID = 18264824.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Libé R, Chanson P: [Endocrine tumors of the pancreas (EPTs) in multiple endocrine neoplasia (MEN1): up-date on prognostic factors, diagnostic procedures and treatment]. Ann Endocrinol (Paris); 2007 Jun;68 Suppl 1:1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine tumors of the pancreas (EPTs) in multiple endocrine neoplasia (MEN1): up-date on prognostic factors, diagnostic procedures and treatment].
  • [Transliterated title] Les tumeurs endocrines du pancréas lors de la néoplasie endocrinienne multiple type 1 (NEM1): actualités sur les facteurs pronostiques, l'imagerie et le traitement.
  • Endocrine pancreatic tumors (EPTs) are uncommon tumors, representing 1-2% of all pancreatic neoplasms.
  • They are categorized on the basis of their clinical features into functioning and non-functioning tumors.
  • The most prevalent are the gastrinomas (20-60%), then the insulinomas (5-10%), the glucagonamas and VIPomas (6-10%), whereas the nonfunctioning EPTs are present in 20-40% of patients.
  • Among the different imaging techniques, echoendoscopy, computed tomography (CT) and magnetic resonance imaging (MRI) are indicated for the detection of the primary tumor, but (III)In-octreotide scintigraphy has the highest sensitivity for detecting metastases.
  • The choice of treatment is still debated and is different when the tumor occurs as a part of the MEN syndrome.
  • The medical treatment includes somatostatin analogues (SA), chemotherapy and interferon-alpha (IFN-alpha).
  • SA seem to improve the symptoms and have an antiproliferative effect, the most striking effect being seen in patients with VIPomas.
  • Chemotherapy, which is generally proposed as a combination of streptozotocin (STZ) and 5-fluorouracil (5-FU) or doxorubicin, is indicated when the tumors tend to grow.
  • Interferon-alpha (IFN-alpha) stimulates the immune system, blocks the tumor cells in the G1/S-phase of the cell cycle, inhibits protein and hormone synthesis and inhibits angionenesis.
  • Treatment with IFN has been shown to produce symptomatic response in 40-60% of patients, a biochemical response in 30-60% and tumor shrinkage in 10-15%.
  • [MeSH-major] Carcinoma, Islet Cell. Multiple Endocrine Neoplasia Type 1

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Endocrinol (Paris). 2008 Nov;69(5):459-60
  • (PMID = 17961653.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


48. Fendrich V, Bartsch DK: [Diagnosis and surgical management of neureondocrine pancreatic tumours]. Zentralbl Chir; 2010 Jun;135(3):210-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical management of neureondocrine pancreatic tumours].
  • The only chance of cure for patients with pancreatic endocrine tumours (PETs) is complete surgical removal not only of the primary tumour, but also of local or distant metastases.
  • This is true for gastrinomas, vipomas, glucagonomas, somatostatinomas and non-functional pancreatic endocrine tumours.
  • An aggressive surgical approach leads to cure in patients with benign tumours, and may achieve long-term survival in patients with malignant NPTs.
  • [MeSH-major] Hyperinsulinism / surgery. Insulinoma / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Laparoscopy. Lymph Node Excision. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Pancreas / pathology. Pancreas / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart, New York.
  • (PMID = 20549584.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


49. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ: Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging; 2008 Apr;35(4):749-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Receptor radionuclide therapy is a promising treatment modality for patients with neuroendocrine tumors for whom alternative treatments are limited.
  • Four hundred seventy-six patients with gastroenteropancreatic neuroendocrine tumors and three patients with metastatic pheochromocytoma were included for analysis.
  • One patient had a metastatic hormone-producing small intestinal carcinoid; two patients had metastatic, hormone-producing bronchial carcinoids; two patients had vasoactive intestinal polypeptide-producing pancreatic endocrine tumors (VIPomas); and one patient had a metastatic pheochromocytoma.
  • [MeSH-major] Endocrine System Diseases / etiology. Gastrointestinal Neoplasms / radiotherapy. Neuroectodermal Tumors, Primitive / radiotherapy. Neuroendocrine Tumors / radiotherapy. Octreotide / analogs & derivatives. Organometallic Compounds / adverse effects. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1988;527:518-27 [2839088.001]
  • [Cites] Ann Thorac Surg. 1993 Dec;56(6):1403-5 [8267450.001]
  • [Cites] Endocr J. 1994 Apr;41(2):155-60 [7951563.001]
  • [Cites] Mt Sinai J Med. 1994 Sep;61(4):349-55 [7969229.001]
  • [Cites] Med Clin North Am. 1995 Jan;79(1):131-53 [7808088.001]
  • [Cites] Int Anesthesiol Clin. 1997 Fall;35(4):129-42 [9444534.001]
  • [Cites] Lancet. 1998 Sep 5;352(9130):799-805 [9737302.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):71-5 [15656803.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • [Cites] J Endocrinol Invest. 2006 Jun;29(6):563-7 [16840837.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:18 [17428340.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1854-60 [17546456.001]
  • [Cites] Intensive Care Med. 2000 Feb;26(2):254 [10784323.001]
  • [Cites] Chest. 2000 Oct;118(4):1221-3 [11035703.001]
  • [Cites] Clin Radiol. 2001 Mar;56(3):250-1 [11247706.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1319-25 [11585290.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):53-7 [11790981.001]
  • [Cites] J Clin Gastroenterol. 2003 Jan;36(1):87-8 [12488725.001]
  • [Cites] Ann Clin Biochem. 2003 Nov;40(Pt 6):612-27 [14629799.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Front Horm Res. 2004;31:61-75 [14674305.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] N Engl J Med. 1985 Nov 7;313(19):1229-30 [2865675.001]
  • (PMID = 18210106.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / (177lutetium-DOTA(O)Tyr3)octreotate; 0 / Organometallic Compounds; 0 / Radioisotopes; 5H0DOZ21UJ / Lutetium; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2668649
  •  go-up   go-down


50. Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep; 2009 Apr;11(2):119-27
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the pancreas.
  • Pancreatic endocrine tumors are rare neoplasms accounting for less than 5% of pancreatic malignancies.
  • They are broadly classified into either functioning tumors (insulinomas, gastrinomas, glucagonomas, VIPomas, and somatostatinomas) or nonfunctioning tumors.
  • The diagnosis of these tumors is difficult and requires a careful history and examination combined with laboratory tests and radiologic imaging.
  • Signs and symptoms are usually related to hormone hypersecretion in the case of functioning tumors and to tumor size or metastases with nonfunctioning tumors.
  • Surgical resection remains the treatment of choice even in the face of metastatic disease.
  • Further development of novel diagnostic and treatment modalities offers potential to greatly improve quality of life and prolong disease-free survival for patients with pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell. Carcinoma, Islet Cell. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19281699.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins; 0 / Insulin; 51110-01-1 / Somatostatin; 9007-92-5 / Glucagon
  • [Number-of-references] 44
  •  go-up   go-down


51. Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, Cheung-Lau G, Pisegna JR, Gressens P, Lawson G, Waschek JA: Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides; 2007 Sep;28(9):1688-99
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.
  • In 1970, Drs. Said and Mutt isolated a novel peptide from porcine intestinal extracts with powerful vasoactive properties, and named it vasoactive intestinal peptide (VIP).
  • Since then, the biological actions of VIP in the gut as well as its signal transduction pathways have been extensively studied.
  • A variety of in vitro and in vivo studies have indicated that VIP, expressed in intrinsic non-adrenergic non-cholinergic (NANC) neurons, is a potent regulator of gastrointestinal (GI) motility, water absorption and ion flux, mucus secretion and immune homeostasis.
  • These VIP actions are believed to be mediated mainly by interactions with highly expressed VPAC(1) receptors and the production of nitric oxide (NO).
  • Furthermore, VIP has been implicated in numerous physiopathological conditions affecting the human gut, including pancreatic endocrine tumors secreting VIP (VIPomas), insulin-dependent diabetes, Hirschsprung's disease, and inflammatory bowel syndromes such as Crohn's disease and ulcerative colitis.
  • To further understand the physiological roles of VIP on the GI tract, we have begun to analyze the anatomical and physiological phenotype of C57BL/6 mice lacking the VIP gene.
  • Herein, we demonstrate that the overall intestinal morphology and light microscopic structure is significantly altered in VIP(-/-) mice.
  • Alcian blue staining indicated that the latter cells were deficient in mucus secretion in VIP(-/-) mice.
  • Physiologically, the VIP(-/-) mice showed an impairment in intestinal transit.
  • Moreover, unlike WT C57BL/6 mice, a significant percentage of VIP(-/-) mice died in the first postnatal year with overt stenosis of the gut.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9244-54 [12417650.001]
  • [Cites] Circulation. 2007 Mar 13;115(10):1260-8 [17309917.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):961-71 [12671893.001]
  • [Cites] Neurogastroenterol Motil. 2003 Jun;15(3):239-42 [12787332.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R939-49 [12855416.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Curr Pharm Des. 2004;10(20):2483-97 [15320758.001]
  • [Cites] Science. 1970 Sep 18;169(3951):1217-8 [5450698.001]
  • [Cites] Science. 1971 Oct 22;174(4007):422-4 [5111998.001]
  • [Cites] Am J Physiol. 1980 Mar;238(3):G190-6 [6245588.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2529-33 [6248206.001]
  • [Cites] Am J Physiol. 1984 Feb;246(2 Pt 1):G204-8 [6141741.001]
  • [Cites] Eur J Biochem. 1984 Feb 15;139(1):181-7 [6321173.001]
  • [Cites] Am J Med. 1987 May 29;82(5B):37-48 [3035922.001]
  • [Cites] Gut. 1989 May;30(5):600-4 [2731751.001]
  • [Cites] Experientia. 1989 Dec 1;45(11-12):1102-5 [2557231.001]
  • [Cites] J Auton Nerv Syst. 1990 Dec;31(3):219-29 [2084186.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):501-9 [1371513.001]
  • [Cites] Endocrinology. 1992 Sep;131(3):1188-94 [1324153.001]
  • [Cites] Histol Histopathol. 1994 Jul;9(3):615-29 [7981507.001]
  • [Cites] Am J Physiol. 1995 Jun;268(6 Pt 1):L1047-51 [7541947.001]
  • [Cites] Dev Neurosci. 1995;17(1):1-7 [7621745.001]
  • [Cites] Ann N Y Acad Sci. 1996 Dec 26;805:290-300; discussion 300-1 [8993411.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):731-7 [9125641.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):269-76 [9218127.001]
  • [Cites] Mol Med. 1997 Dec;3(12):826-35 [9440116.001]
  • [Cites] Cell Signal. 1998 Jan;10(1):13-26 [9502113.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):1-5 [9662242.001]
  • [Cites] Arch Pathol Lab Med. 1998 Aug;122(8):721-5 [9701334.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8235-42 [15623599.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G262-8 [16123200.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Oct;291(4):G728-34 [16959956.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Jun;278(6):G974-80 [10859228.001]
  • [Cites] Peptides. 2000 Oct;21(10):1565-82 [11068106.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):1183-7 [11396161.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 2001;234:53-60 [11713981.001]
  • [Cites] Gut. 2002 Mar;50(3):355-60 [11839714.001]
  • [Cites] Regul Pept. 2002 May 30;105(3):145-54 [11959368.001]
  • [Cites] J Gastroenterol. 2002;37(4):239-46 [11993506.001]
  • [Cites] Peptides. 2003 Jan;24(1):163-77 [12576099.001]
  • (PMID = 17606312.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD034475; United States / NICHD NIH HHS / HD / HD006576-250021; United States / NICHD NIH HHS / HD / HD034475-03; United States / NICHD NIH HHS / HD / P01 HD006576-240021; United States / NICHD NIH HHS / HD / HD034475-08; United States / NICHD NIH HHS / HD / HD006576-280021; United States / NICHD NIH HHS / HD / R01 HD034475-09; United States / NICHD NIH HHS / HD / HD034475-04; United States / NICHD NIH HHS / HD / HD006576-270021; United States / NICHD NIH HHS / HD / P01 HD006576-270021; United States / NICHD NIH HHS / HD / HD034475-09; United States / NICHD NIH HHS / HD / HD006576-290011; United States / NICHD NIH HHS / HD / P01 HD006576-260021; United States / NICHD NIH HHS / HD / P01 HD006576; United States / NICHD NIH HHS / HD / R01 HD034475-05A1; United States / NICHD NIH HHS / HD / R01 HD034475-07; United States / NICHD NIH HHS / HD / HD006576-240021; United States / NICHD NIH HHS / HD / HD034475-07; United States / NICHD NIH HHS / HD / HD006576-27S10021; United States / NICHD NIH HHS / HD / HD34475; United States / NICHD NIH HHS / HD / R01 HD034475-06; United States / NICHD NIH HHS / HD / R01 HD034475-04; United States / NICHD NIH HHS / HD / P01 HD006576-290011; United States / NICHD NIH HHS / HD / P01 HD006576-250021; United States / NICHD NIH HHS / HD / P01 HD006576-280021; United States / NICHD NIH HHS / HD / HD034475-06; United States / NICHD NIH HHS / HD / HD034475-05A1; United States / NICHD NIH HHS / HD / HD006576-260021; United States / NICHD NIH HHS / HD / P01 HD006576-27S10021; United States / NICHD NIH HHS / HD / R01 HD034475-03; United States / NICHD NIH HHS / HD / HD0657; United States / NICHD NIH HHS / HD / R01 HD034475-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  • [Other-IDs] NLM/ NIHMS30935; NLM/ PMC2042583
  •  go-up   go-down


52. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg; 2006 Dec;244(6):845-51; discussion 852-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors.
  • OBJECTIVE: To evaluate the outcome of reoperations in patients with duodenopancreatic neuroendocrine tumors (PETs) in a tertiary referral center.
  • RESULTS: A total of 33 patients with a median age of 42 years were identified for this study: 13 patients had gastrinomas, 12 patients had nonfunctional islet cell tumors, 6 patients had insulinomas, and 2 patients had vipomas; 24 patients had sporadic NETs, 9 patients had a MEN-1-syndrome; 27 patients had histologically verified malignant tumors; 33 initial operations and 50 reoperations were performed.
  • The initial procedures comprised 27 resections of the primary tumor and 6 explorative laparotomies; 28 of all reoperations were resections of distant metastases, including 15 liver resections; 19 resections of the pancreas or duodenum were performed during reoperations.
  • After a median follow-up of 124 months (range, 16-384 months), 27 of 33 patients are still alive, 12 without evidence of disease.
  • All 6 patients with benign tumors are still alive.
  • The 5-, 10-, and actuarial 25-year survival rate for patients with malignant tumors were 81%, 72%, and 36%, respectively.
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Nov;24(11):1418-24 [11038216.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):67-79 [11907468.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):855-62 [12417506.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Apr 23;129(17):941-6 [15083396.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Surgery. 1988 Dec;104(6):1011-7 [2904180.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):393-8; discussion 398-9 [1973323.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):320-8; discussion 328-30 [7916560.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] World J Surg. 1998 Jul;22(7):666-71; discussion 671-2 [9606279.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1353-60 [11038206.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Surgery. 1996 Dec;120(6):1055-62; discussion 1062-3 [8957495.001]
  • [Cites] Gut. 2005 Feb;54(2):289-96 [15647196.001]
  • [Cites] Surgery. 2004 Dec;136(6):1205-11 [15657577.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):170-85 [15719379.001]
  • [Cites] Chirurg. 2005 Mar;76(3):217-26 [15688179.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):577-83 [16183528.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):699-704 [16253894.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81 [16253899.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98 [16253900.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):819-30 [16253903.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] Surgery. 2001 Feb;129(2):170-5 [11174710.001]
  • (PMID = 17122609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1856628
  •  go-up   go-down


53. Gao C, Fu X, Pan Y, Li Q: Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Dig Surg; 2010 Aug;27(3):197-204
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases.
  • OBJECTIVES: To review the clinical data of a group of patients with pancreatic neuroendocrine tumors (pNETs) and to investigate the role of surgery in the treatment for pNETs by analyzing clinical manifestations and postoperative course of this rare disease.
  • Patients' data related to demographics and characteristics, diagnostic studies, surgical and tumor characteristics and survival were retrospectively reviewed.
  • RESULTS: Forty-six patients (41.1%) had a well-differentiated neuroendocrine tumor (WDT), 44 (48.2%) a well-differentiated neuroendocrine carcinoma (WD-Ca) and 12 (10.7%) a poorly differentiated neuroendocrine carcinoma (PD-Ca).
  • Nonfunctional tumors were seen in 65 (58.0%) patients, whereas functional tumors were found in 47 (42.0%) patients, including 26 insulinomas, 17 gastrinomas, 2 VIPomas, 1 glucagonoma, and 1 ACTHoma.
  • The common postoperative complications were pancreatic fistula (15.2%), wound infection (13.4%) and delayed gastric emptying (6.3%).
  • Twenty-six (55.3%) of the 47 functional tumors were malignant, whereas 40 (61.5%) of the 65 nonfunctional tumors were malignant.
  • Survival was significantly related to the type of neuroendocrine tumor (p = 0.001).
  • The 5-year survival rate differed significantly between patients with tumor node metastasis (TNM) stage I and II disease and those with stage III and IV tumors (p = 0.011).
  • Patients with stage III had better prognosis than those with stage IV tumors (p = 0.007).
  • Malignant cases should be treated with aggressive radical surgery to achieve complete tumor resection and potential for long-term survival.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571266.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Langer P, Fendrich V, Bartsch DK: [Minimally invasive resection of neuroendocrine pancreatic tumors]. Chirurg; 2009 Feb;80(2):105-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimally invasive resection of neuroendocrine pancreatic tumors].
  • Pancreatic endocrine tumors (PET) are a heterogeneous group of lesions with an annual incidence of 0.1 to 0.4 per 100,000.
  • They account for 2-4% of pancreatic neoplasms.
  • Preoperative localization, intraoperative laparoscopic ultrasonography, and considerable experience in pancreatic endocrine surgery and sophisticated laparoscopic techniques are essential for successful laparoscopic treatment of these tumors.
  • Insulinomas and small nonfunctioning PET in the pancreatic body or tail or near the surface of the pancreatic head and not in contact with the portal vein or the main pancreatic duct are suited to a laparoscopic approach.
  • Patients with MEN1 who have insulinomas or small nonfunctioning PET may also benefit from a laparoscopic spleen-preserving distal pancreatic resection.
  • Neither sporadic and MEN1-associated gastrinomas nor the very rare glucagonomas and vasoactive intestinal peptide-producing tumors (vipomas), which are often large and malignant, should also be tackled laparoscopically.
  • [MeSH-major] Carcinoma, Neuroendocrine / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Insulinoma / diagnosis. Insulinoma / surgery. Laparoscopy / methods. Male. Minimally Invasive Surgical Procedures / methods. Multiple Endocrine Neoplasia Type 1 / diagnosis. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatectomy / methods. Pancreatitis, Chronic / diagnosis. Pancreatitis, Chronic / surgery. Positron-Emission Tomography. Ultrasonography. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2008 May;32(5):904-17 [18264824.001]
  • [Cites] World J Surg. 2005 Feb;29(2):203-7 [15650799.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2008 Feb;18(1):13-8 [18287976.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):279-83 [11525376.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):103-8 [17008952.001]
  • [Cites] World J Surg. 2004 Dec;28(12 ):1239-47 [15517485.001]
  • [Cites] Ann Surg. 2008 Sep;248(3):438-46 [18791364.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Semin Laparosc Surg. 1998 Sep;5(3):168-79 [9787203.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):393-8; discussion 398-9 [1973323.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):752-60 [16773762.001]
  • [Cites] Am J Med. 1986 Dec 22;81(6B):14-22 [2879446.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] Dtsch Med Wochenschr. 2005 Mar 11;130(10 ):514-8 [15744643.001]
  • [Cites] Surg Today. 2007;37(7):535-45 [17593471.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] J Am Coll Surg. 2007 Aug;205(2):222-30 [17660068.001]
  • [Cites] Gut. 1978 Jul;19(7):672-7 [150363.001]
  • [Cites] Surg Endosc. 1994 May;8(5):408-10 [7915434.001]
  • [Cites] Surgery. 1991 Dec;110(6):1086-91; discussion 1091-3 [1745977.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3 [17122609.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Feb 2;132(5):195-200 [17252361.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):138-44 [8342993.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):881-91 [9735139.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81 [16253899.001]
  • [Cites] Ann Surg. 2004 May;239(5):617-25; discussion 626 [15082965.001]
  • (PMID = 19099267.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


55. Simonenko VB, Dulin PA, Makanin MA: [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors]. Klin Med (Mosk); 2006;84(4):4-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
  • Other cyclic analogues with similar sensitivity and activity profile, such as lanreotide (somatulin), somatostatin-14, and SOM 230, have been developed as well.
  • Sandostatin therapy is indicated to patients with functionally active neuroendocrine tumors of the stomach, duodenum, small bowel, or appendix.
  • Glucagonomas, vipomas, and, to a lesser degree, gastrinomas and metastatic insulinomas are examples of functionally active endocrine pancreatic tumors that should be treated with sandostatin.
  • Other syndromes, which should be treated with octreotide, include ectopic secretion of adrenocorticotropic hormone in Cushing syndrome, oncogenic osteomalacia, and hypercalciemia resulting from ectopic secretion of parathyroid-like peptide.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy. Pancreatic Neoplasms / drug therapy. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755846.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin
  • [Number-of-references] 25
  •  go-up   go-down


56. Ascuña Vásquez E, López Mondejar P, Mora A, Martín Hidalgo A: [Pancreatic VIPoma with atypical clinical course: apropos of a case]. Endocrinol Nutr; 2009 Feb;56(2):100-1
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic VIPoma with atypical clinical course: apropos of a case].
  • [Transliterated title] VIPoma pancreático de evolución atípica: a propósito de un caso.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Vipoma / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / blood. Cholecystectomy. Combined Modality Therapy. Dehydration / etiology. Diarrhea / etiology. Emergencies. Gastrectomy. Humans. Hypokalemia / etiology. Male. Middle Aged. Octreotide / therapeutic use. Pancreaticoduodenectomy. Remission Induction. Splenectomy

  • Genetic Alliance. consumer health - VIPoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627720.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; RWM8CCW8GP / Octreotide
  •  go-up   go-down


57. Doi R, Tsukada T: [Vasoactive intestinal peptide-producing tumor (ViPoma)]. Nihon Rinsho; 2006 Sep 28;Suppl 3:358-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vasoactive intestinal peptide-producing tumor (ViPoma)].
  • [MeSH-major] Pancreatic Neoplasms. Vasoactive Intestinal Peptide / secretion. Vipoma

  • Genetic Alliance. consumer health - VIPoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022564.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  • [Number-of-references] 11
  •  go-up   go-down


58. Jackson C, Buchman AL: Calcitonin-secreting VIPoma. Dig Dis Sci; 2005 Dec;50(12):2203-6
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcitonin-secreting VIPoma.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Calcitonin / biosynthesis. Vipoma / pathology
  • [MeSH-minor] Biopsy, Needle. Chronic Disease. Diarrhea / diagnosis. Diarrhea / etiology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laparoscopy / methods. Middle Aged. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - VIPoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416161.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-12-9 / Calcitonin
  •  go-up   go-down


59. Li JT, Fang HQ, Liu XL, Tang Z, Xu J, Zhang SZ, Ma R, Zhang LY, Wang JW, Liu YB, Peng SY: Is radiofrequency ablation justified for liver metastatic VIPoma patient undergoing Whipple procedure? Chin Med J (Engl); 2010 Aug 5;123(15):2151-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiofrequency ablation justified for liver metastatic VIPoma patient undergoing Whipple procedure?
  • [MeSH-major] Catheter Ablation / adverse effects. Catheter Ablation / methods. Liver Neoplasms / surgery. Liver Neoplasms / therapy. Vipoma / surgery. Vipoma / therapy

  • Genetic Alliance. consumer health - VIPoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819560.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement